

2021

Chemtrade Logistics Income Fund

2021 First Quarter Report

CHEMTRADE LOGISTICS INCOME FUND MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2021

The information in this Management's Discussion and Analysis, or MD&A, is intended to assist the reader in the understanding and assessment of the trends and significant changes in the results of operations and financial condition of Chemtrade Logistics Income Fund (the "Fund"). Throughout this MD&A, the term "Chemtrade" refers to the Fund and its consolidated subsidiaries. The terms "we", "us" or "our" similarly refers to Chemtrade. This MD&A should be read in conjunction with the unaudited condensed consolidated interim financial statements of Chemtrade for the three months ended March 31, 2021, the audited consolidated financial statements of Chemtrade for the year ended December 31, 2020 and the annual MD&A for the year ended December 31, 2020.

Chemtrade's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). Chemtrade's reporting currency is the Canadian dollar. In this MD&A, per unit amounts are calculated using the weighted average number of units outstanding for the applicable period unless otherwise indicated. This MD&A is current as at May 10, 2021 and was approved by the Board of Trustees (the "Board") on that date.

Caution Regarding Forward-Looking Statements

Certain statements contained in this MD&A constitute forward-looking statements within the meaning of certain securities laws, including the Securities Act (Ontario). Forward-looking statements can be generally identified by the use of words such as "anticipate", "continue", "estimate", "expect", "expected", "intend", "may", "will", "project", "plan", "should", "believe" and similar expressions. Specifically, forward-looking statements in this MD&A include statements respecting certain future expectations about: statements relating to the impact of the COVID-19 pandemic and its variants on Chemtrade including the timing and extent of economic recovery and its effects on Chemtrade; the amount of any long-term incentive compensation; the ability to finalize the terms of settlement and obtain the approval of the relevant governmental entities and courts of the derivative actions settlement; the effect of changes in the interest rate, the exchange rate and the Fund's ability to offset US dollar denominated debt; the ability of Chemtrade to access tax losses and tax attributes; the tax characterization of planned distributions; capital expenditures; sources, use, sufficiency and availability of cash flows; the intention to adopt IBOR reform and its impacts; the effectiveness of disclosure controls procedures and internal controls and of their design and implementation; and statements in the Financial Outlook section, including: the Fund's intention to reinstate guidance and the timing thereof; the ability of our plants to operate well during 2021 and in particular, our North Vancouver chlor-alkali plant; the 2021 levels of demand and sales volumes of our products (water solutions products, ultrapure acid, caustic soda, HCI, sodium chlorate) and other commodities (gasoline); expectations for 2021 prices of certain products (caustic and sodium chlorate) and of water solutions raw materials; our ability to pass cost increases to customers; rates for refinery utilization and fracking activity; the timing of movements in the price of caustic soda; our ability to recover ultrapure volume, currency impacts and rising production costs and the timing thereof; and the expected 2021 range of capital expenditures, lease payments, cash interest and cash taxes. Forward-looking statements in this MD&A describe the expectations of Chemtrade as of the date hereof. These statements are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements for a variety of reasons, including without limitation the risks and uncertainties detailed under the "RISK FACTORS" section of the Fund's latest Annual Information Form and the "RISKS AND UNCERTAINTIES" section below.

Although Chemtrade believes the expectations reflected in these forward-looking statements and the assumptions upon which they are based are reasonable, no assurance can be given that actual results will be consistent with such forward-looking statements, and they should not be unduly relied upon. With respect to the forward-looking statements contained in this MD&A, Chemtrade has made assumptions regarding: certain key elements as set out in the Financial Outlook section, including the assumed 2021 North American MECU production volumes and sodium chlorate volumes; and the 2021 average North East Asia spot price for caustic soda; there being no significant disruptions affecting the operations of Chemtrade, whether due to labour disruptions, supply disruptions, power disruptions, transportation disruptions, damage to equipment or otherwise; the ability of Chemtrade to obtain products, raw materials, equipment, transportation, services and supplies in a timely manner to carry out its activities and at prices consistent with current levels or in line with Chemtrade's expectations; the timely receipt of required regulatory approvals; the cost of regulatory and environmental compliance being consistent with current levels or in line with Chemtrade to successfully access tax losses and tax attributes; the ability of Chemtrade to obtain financing on acceptable terms; currency, exchange and interest rates being consistent with current levels or in line with Chemtrade's expectations; and global economic performance.

Except as required by law, Chemtrade does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or for any other reason. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement.

Recent Developments

Issuance of the Fund units

During the first quarter of 2021, Chemtrade completed an equity offering of 9,800,000 units at a price of \$7.15 per unit, resulting in total gross proceeds of \$70.1 million. Chemtrade incurred issuance costs of \$2.5 million, net of tax recovery of \$1.2 million, which included underwriters' fees and other expenses relating to the offering. Proceeds from the offering were used to repay outstanding indebtedness under Chemtrade's senior credit facilities ("Credit Facilities") and for general trust purposes.

Amendment of Credit Facilities terms

In May 2021, Chemtrade modified certain terms of its Credit Facilities including negotiating an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2023.

Chemtrade has established a Pandemic Steering Team (the "Team") to assess, monitor and manage the impact of the COVID-19 virus on its business and share information across the organization. Operations have been adjusted and actions taken as needed to protect the health of employees, suppliers and visitors.

The Team developed policies, procedures, protocols, assessment tools and guidance to assist all manufacturing facilities and offices, as well as employees working from home. The Team has disseminated health screening tools and isolation guides for employees and instituted contact tracing of our employees for any known cases of the virus within Chemtrade's employee population. The Team also instituted decontamination procedures when required, acquired and installed or disseminated personal protective equipment for employees, and implemented a business travel policy. Chemtrade's health and safety personnel have worked in cooperation with public health authorities and Chemtrade's suppliers and customers to share information and best practices, and promote employee safety and confidence to work. Working protocols and communication tools are now well established. These address office opening protocols, social distancing and personal protective equipment requirements, facility assessments, cleaning and disinfection protocols, and employee training and communications.

From the onset of the COVID-19 pandemic and related restrictions, Chemtrade's business was deemed an essential service pursuant to the various provincial and state orders and its facilities have continued to operate. For the most part, Chemtrade's customers, suppliers and service providers, including transportation, have also continued to operate.

Demand for certain of Chemtrade's products such as water treatment chemicals has not been affected by the pandemic, whereas demand for most other products has been modestly lower. During 2020, the biggest impact of the pandemic on Chemtrade's business was caused by government orders restricting non-essential travel and by people working from home. Both of these drastically reduced demand for gasoline which has resulted in lower demand for Chemtrade's regenerated ("Regen") acid services, as oil refineries are operating at significantly reduced rates. Also, with large numbers of people working from home and not attending school, demand for printing paper has declined. Printing paper is a significant end-market for pulp in North America. Chemtrade's sodium chlorate is used to bleach pulp and the reduced demand for pulp has resulted in reduced demand for sodium chlorate. Finally, the generally lower levels of economic activity have resulted in reduced demand for merchant sulphuric acid, which is one of the most widely used chemicals in the world.

Given the high degree of economic uncertainty caused by the COVID-19 pandemic, in April 2020, Chemtrade suspended its earnings guidance (see **Financial Outlook**). Chemtrade also reduced its monthly distribution rate by fifty percent effective with the March 2020 distribution which was paid at the end of April 2020. Chemtrade negotiated two amendments to its credit agreement; the first in May 2020 and the second in May 2021, which provide additional covenant room. Chemtrade continues to closely monitor its accounts receivable and they are consistent with historic levels.

During the first quarter of 2021, refinery operating rates were negatively affected by the California stay-at-home orders. These were subsequently lifted, however, it remains difficult to predict whether similar restrictions will be imposed as new variants of COVID-19 are discovered.

As increasing amounts of vaccines are administered, particularly in the U.S., demand for gasoline is improving. As the U.S. economy starts to recover, demand for paper is also improving.

Financial Highlights

These financial highlights have been presented in accordance with IFRS, except where noted.

	Three month	is ended
(\$'000 except per unit amounts)	March 31, 2021	March 31, 2020
Revenue	\$ 312,440 \$	366,901
Net loss (1)	\$ (20,448) \$	(97,875)
Net loss per unit (1)(3)	\$ (0.21) \$	(1.06)
Diluted net loss per unit (1)(3)	\$ (0.21) \$	(1.06)
Total assets	\$ 2,453,674 \$	2,837,909
Long-term debt	\$ 741,205 \$	945,341
Convertible unsecured subordinated debentures	\$ 510,352 \$	386,658
Adjusted EBITDA (4)	\$ 55,428 \$	80,880
Adjusted EBITDA per unit (3)(4)	\$ 0.58 \$	0.87
Cash flows (used in) from operating activities (2)	\$ (6,396) \$	30,321
Cash flows (used in) from operating activities per unit (2)(3)(4)	\$ (0.07) \$	0.33
Adjusted cash flows from operating activities (4)	\$ 26,071 \$	49,274
Adjusted cash flows from operating activities per unit (3)(4)	\$ 0.27 \$	0.53
Distributable cash after maintenance capital expenditures (4)	\$ 17,884 \$	38,231
Distributable cash after maintenance capital expenditures per unit (3)(4)	\$ 0.19 \$	0.41
Distributions declared	\$ 14,554 \$	23,150
Distributions declared per unit (5)	\$ 0.15 \$	0.25
Distributions paid, net of distributions reinvested	\$ 12,157 \$	27,780
Distributions paid, net of distributions reinvested per unit (6)	\$ 0.15 \$	0.30

⁽¹⁾ Results for the three months ended ended March 31, 2020 include a goodwill impairment charge of \$56,000, or \$0.60 per unit. See **Goodwill Impairment**.

95,673,137

92,601,062

Non-IFRS Measures

EBITDA and Adjusted EBITDA -

Management defines EBITDA as net earnings before any deduction for net finance costs, income taxes, depreciation and amortization. Adjusted EBITDA also excludes other non-cash charges such as impairment, change

⁽²⁾ In 2021, Chemtrade reclassified certain items into net cash flows (used in) from operating activities. Comparatives have been restated to conform to current period presentation.

⁽³⁾ Based on weighted average number of units outstanding for the period of:

⁽⁴⁾ See Non-IFRS Measures.

⁽⁵⁾ Based on actual number of units outstanding on record date.

⁽⁶⁾ Based on actual number of units eligible for cash distributions on record date.

in environmental liability, net gains and losses on the disposal and write-down of property, plant and equipment ("PPE"), and unrealized foreign exchange gains and losses. EBITDA and Adjusted EBITDA are metrics used by many investors and analysts to compare organizations on the basis of ability to generate cash from operations. Management considers Adjusted EBITDA (as defined) to be an indirect measure of operating cash flow, which is a significant indicator of the success of any business. Adjusted EBITDA is not intended to be representative of cash flow from operations or results of operations determined in accordance with IFRS or cash available for distribution.

EBITDA and Adjusted EBITDA are not recognized measures under IFRS. Chemtrade's method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other income trusts or companies, and accordingly may not be comparable to similar measures presented by other organizations. A reconciliation of EBITDA and Adjusted EBITDA to net loss follows:

Three months e	

(\$'000)	Marc	ch 31, 2021 Mar	ch 31, 2020
Net loss	\$	(20,448) \$	(97,875)
Add:			
Depreciation and amortization		62,393	63,917
Net finance costs		21,498	67,452
Income tax recovery		(8,596)	(21,121)
EBITDA		54,847	12,373
Add:			
Impairment of goodwill		_	56,000
Change in environmental liability		_	3,381
Net loss (gain) on disposal and write-down of PPE		151	(482)
Unrealized foreign exchange loss		430	9,608
Adjusted EBITDA	<u> </u>	55,428 \$	80,880

Cash Flow -

The following table is derived from, and should be read in conjunction with the condensed consolidated interim statements of cash flows. Management believes this supplementary disclosure provides useful additional information related to the cash flows of Chemtrade including the amount of cash available for distribution to Unitholders, repayment of debt and other investing activities. Certain sub-totals presented within the cash flows table below, such as "Adjusted cash flows from operating activities", "Distributable cash after maintenance capital expenditures" and "Distributable cash after all capital expenditures", are not defined terms under IFRS. These sub-totals are used by Management as measures of internal performance and as a supplement to the condensed consolidated interim statements of cash flows. Investors are cautioned that these measures should not be construed as an alternative to using net earnings as a measure of profitability or as an alternative to the IFRS condensed consolidated interim statements of cash flows. Further, Chemtrade's method of calculating each measure may not be comparable to calculations used by other income trusts or companies bearing the same description.

(\$'000)	March 31, 20	21 March 31, 2	:020
Cash flows (used in) from operating activities (1)	(6,3	396) 30,	,321
(Less) Add:			
Lease payments net of sub-lease receipts	(13,0)28) (13,	,795)
Changes in non-cash working capital and other items (1)	45,4	195 32,	,748
Adjusted cash flows from operating activities	26,0	071 49,	,274
Less:			
Maintenance capital expenditures	8,1	87 11,	,043
Distributable cash after maintenance capital expenditures	17,8	38,	,231
Less:			
Non-maintenance capital expenditures ⁽²⁾	5	582	746
Distributable cash after all capital expenditures	\$ 17,3	302 \$ 37,	,485

⁽¹⁾ In 2021, Chemtrade reclassified certain items into net cash flows (used in) from operating activities. Comparatives have been restated to conform to current period presentation.

Consolidated Operating Results

The Canadian dollar relative to the U.S. dollar was significantly stronger during the first quarter of 2021 (US\$1.00 = \$1.27) compared with the first quarter of 2020 (US\$1.00 = \$1.34). This had a negative impact on the financial results of the first quarter of 2021.

Revenue for the first quarter of 2021 was \$312.4 million, which was \$54.5 million lower than revenue for the first quarter of 2020, which was relatively unaffected by the COVID-19 pandemic. The decrease in revenue for the first quarter is primarily due to lower sales volume of Regen acid, merchant sulphuric acid and ultra pure sulphuric acid in the Sulphur Products and Performance Chemicals ("SPPC") segment, lower sales volumes of sodium chlorate and lower selling prices of caustic soda in the Electrochemicals ("EC") segment and lower sales volumes of water solutions products and of phosphorus pentasulphide in the Water Solutions and Specialty Chemicals ("WSSC") segment. The stronger Canadian dollar had a negative impact of \$12.5 million on revenues during the first quarter of 2021.

Chemtrade's Adjusted EBITDA for the three months ended March 31, 2021 of \$55.4 million, was \$25.5 million lower than Adjusted EBITDA for the same period of 2020. The decrease in Adjusted EBITDA for the three months ended March 31, 2021 is due to higher corporate costs and lower Adjusted EBITDA generated by the operating segments. Adjusted EBITDA for the first quarter was also negatively affected by the severe winter storm experienced in large parts of the U.S. The estimated impact was \$2.8 million. The stronger Canadian dollar had a negative impact of \$2.6 million on Adjusted EBITDA, during the first quarter of 2021.

⁽²⁾ Non-maintenance capital expenditures are: (a) pre-identified or pre-funded, usually as part of a significant acquisition and related financing; (b) considered to expand the capacity of Chemtrade's operations; (c) significant environmental capital expenditures that are considered to be non-recurring; or (d) capital expenditures to be reimbursed by a third party

Net loss for the first quarter of 2021 was \$77.4 million lower than the same period of 2020. The decrease is primarily due to goodwill impairment of \$56.0 million recorded during the first quarter of 2020 (see **Goodwill Impairment**), lower net finance costs in the first quarter of 2021 due to a lower loss from the change in the fair value of convertible unsecured subordinated debentures ("Debentures") (see **Net Finance Costs**) and lower unrealized foreign exchange loss. This was partially offset by lower income tax recovery. (see **Income Taxes**).

Results of Operations by Reportable Segment

SPPC -

Three months ended

(\$'000)	March :	31, 2021	March 31, 202
Revenue	\$	91,967	\$ 113,02
Gross profit		7,223	14,46
Adjusted EBITDA (1)		27,971	34,63
Net (loss) gain on disposal and write down of PPE		(12)	4
EBITDA (1)		27,959	34,68

⁽¹⁾ EBITDA and Adjusted EBITDA are not recognized measures under IFRS. Chemtrade's method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other income trusts or companies, and accordingly may not be comparable to similar measures presented by other organizations. See **Non-IFRS Measures** for further details and a reconciliation of EBITDA and Adjusted EBITDA.

SPPC markets, removes and/or produces merchant, Regen and ultra pure sulphuric acid, sodium hydrosulphite, elemental sulphur, liquid sulphur dioxide, hydrogen sulphide, sodium bisulphite, and sulphides, and provides other processing services. These products are marketed primarily to North American customers.

Revenue for the three months ended March 31, 2021 was \$21.1 million lower than the same period of 2020 primarily due to lower sales volumes for acid products and the impact of the stronger Canadian dollar (\$4.2 million).

The stay-at-home orders and various other measures announced to curb travel, resulted in fewer miles being driven in North America and this led to reduced demand for gasoline which in turn reduced demand for Regen acid as that is used in gasoline production. The COVID-19 pandemic resulted in lower levels of economic activity, which resulted in reduced demand for merchant sulphuric acid, which is one of the most widely used chemicals in the world and used in a variety of applications. Although during the first quarter of 2021, demand for these products has improved from the beginning of the pandemic, demand remained below pre-pandemic levels.

Gross profit during the three months ended March 31, 2021 was \$7.2 million lower than the same period of 2020. The lower gross profit was primarily due to reduced demand and lower sales volumes for Regen acid and merchant acid resulting from the COVID-19 pandemic and lower sales volumes for ultra pure sulphuric acid. As previously disclosed, one of our large end-use customers of ultra pure sulphuric acid decided to obtain acid from an alternate source, resulting in lower sales volumes during the first quarter of 2021 relative to 2020.

In addition to the reduced demand as described above, Adjusted EBITDA was also negatively affected by the severe winter storm experienced in large parts of the U.S. (\$1.7 million) and by the stronger Canadian dollar (\$1.3 million).

Three months ended

(\$'000)	Mar	ch 31, 2021	March 31, 2020
Revenue	\$	98,786	\$ 113,338
Gross profit (loss)		13,811	(42,370)
Adjusted EBITDA (1)		21,803	25,706
Impairment of goodwill		_	(56,000)
Change in environmental liability		_	(3,381)
Net (loss) gain on disposal and write-down of PPE		(82)	457
EBITDA (1)	_	21,721	(33,218)

⁽¹⁾ EBITDA and Adjusted EBITDA are not recognized measures under IFRS. Chemtrade's method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other income trusts or companies, and accordingly may not be comparable to similar measures presented by other organizations. See **Non-IFRS Measures** for further details and a reconciliation of EBITDA and Adjusted EBITDA.

WSSC manufactures and markets a variety of inorganic coagulants used in water treatment, including aluminum sulphate, aluminum chlorohydrate, polyaluminum chloride, and ferric sulphate; and a number of specialty chemicals, including sodium nitrite, potassium chloride, phosphorus pentasulphide, and vaccine adjuvants. These products are marketed primarily to North American customers.

Revenue for the three months ended March 31, 2021 was \$14.6 million lower than the same period of 2020 primarily due to lower sales volumes of water solutions products and specialty chemicals as the severe winter storm experienced in large parts of the U.S. disrupted operations and customers. Additionally, volumes for water solutions products were unusually high during the first quarter of 2020 when customers increased their inventory levels due to the onset of the pandemic. The stronger Canadian dollar had a negative impact of \$4.8 million on revenues.

Gross profit for the three months ended March 31, 2021 was \$13.8 million compared with a \$42.4 million loss for the same period of 2020. This is primarily due to a \$56.0 million impairment of goodwill for water solutions products recorded during the first quarter of 2020 (see **Goodwill Impairment**). Gross profit for the first quarter of 2021 was also negatively affected by the severe winter storm experienced in large parts of the U.S. (\$1.1 million) and by the stronger Canadian dollar (\$1.0 million).

Adjusted EBITDA for the three months ended March 31, 2021 was \$3.9 million lower than the same period of 2020 due to lower sales volumes of water solutions products and phosphorus pentasulphide, which is used in the production of automotive lubricants.

Three months ended

(\$'000)	March 31, 202	1 March 31, 2020
North American sales volumes:		
Sodium chlorate sales volume (000's MT)	Ç	92 102
Chlor-alkali sales volume (000's MECU)	4	11 36
Revenue	\$ 121,68	37 \$ 140,541
Gross (loss) profit	(10	05) 6,853
Adjusted EBITDA (1)	27,17	77 32,933
Net loss on disposal and write-down of PPE	(5	57) (24)
EBITDA (1)	27,12	20 32,909

⁽¹⁾ EBITDA and Adjusted EBITDA are not recognized measures under IFRS. Chemtrade's method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other income trusts or companies, and accordingly may not be comparable to similar measures presented by other organizations. See **Non-IFRS Measures** for further details and a reconciliation of EBITDA and Adjusted EBITDA.

EC manufactures and markets sodium chlorate and chlor-alkali products including caustic soda, chlorine and HCl, largely for the pulp and paper, oil and gas and water treatment industries. These products are marketed primarily to North American and South American customers.

Revenue for the three months ended March 31, 2021 was \$18.9 million lower than the same period of 2020. The lower revenue in the first quarter of 2021 was primarily due to lower sales volumes of sodium chlorate, a decrease of 14% in selling prices for caustic soda, a decrease of 30% in selling prices for HCl and the impact of a stronger Canadian dollar (\$3.6 million).

Gross profit for the three months ended March 31, 2021 was \$7.0 million lower than the same period of 2020. Gross profit during 2021 was negatively affected by lower sales volumes of sodium chlorate and lower chlor-alkali selling prices relative to 2020 and by the impact of the stronger Canadian dollar (\$1.3 million).

The factors that affected gross profit also resulted in Adjusted EBITDA for the three months ended March 31, 2021 being \$5.8 million lower than the same period of 2020.

Three months ended

(\$'000)	Mar	ch 31, 2021	March 31, 2020
Cost of services	\$	21,523	\$ 12,391
Adjusted EBITDA (1)		(21,523)	(12,391)
Unrealized foreign exchange loss		(430)	(9,608)
EBITDA (1)		(21,953)	(21,999)

⁽¹⁾ EBITDA and Adjusted EBITDA are not recognized measures under IFRS. Chemtrade's method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other income trusts or companies, and accordingly may not be comparable to similar measures presented by other organizations. See **Non-IFRS Measures** for further details and a reconciliation of EBITDA and Adjusted EBITDA.

The Corporate segment includes the administrative costs of corporate activities such as treasury, finance, information technology, human resources, legal and risk management, and environmental, health and safety support, which are not directly allocable to an operating segment.

For the three months ended March 31, 2021, corporate costs, excluding unrealized foreign exchange gains and losses were \$9.1 million higher than the same period of 2020. During the first quarter of 2021, Chemtrade's unit price appreciated, whereas during the first quarter of 2020, it declined. This resulted in Long Term Incentive Plan ("LTIP") and Deferred Unit Plan ("DUP") costs being \$11.1 million and \$2.4 million higher, respectively, during the first quarter of 2021 relative to 2020. Also, corporate costs in the first quarter of 2021 include \$3.0 million related to the retirement of the former Chief Executive Officer ("CEO"). This was partially offset by a \$4.7 million government grant recognized in relation to the Canada Emergency Wage Subsidy ("CEWS") and the Canada Emergency Rent Subsidy ("CERS") programs and reduced discretionary spending in the first quarter of 2021 relative to 2020.

Corporate costs include LTIP expenses, which relate to the 2019 - 2021, 2020 - 2022 and 2021 - 2023 LTIPs which Chemtrade operates and pursuant to which it grants cash awards based on certain criteria. The 2019-2021 LTIP payout is payable at the beginning of 2022. The 2020 - 2022 LTIP payout is payable at the beginning of 2022 and 2023. The 2021 - 2023 LTIP payout is payable at the beginning of 2024. The LTIP awards have a performance based component and a restricted share unit component. The performance based component of the 2019 - 2021 LTIP awards is based on total Unitholder return over a performance period, EBITDA growth and total return to Chemtrade's Unitholders relative to the total return of companies comprising the S&P/TSX Dividend Composite Index. The performance based component of the 2020 - 2022 and 2021 - 2023 LTIP awards is based on return on investment capital improvement and total return to Chemtrade's Unitholders relative to the total return of companies comprising the S&P/TSX Dividend Composite Index. Total Unitholder return consists of changes in unit price and distributions paid to Unitholders. The restricted share unit component of the LTIP awards is a phantom plan which is payable in cash at the end of the performance period. The nature of these calculations makes it difficult to forecast the amount of LTIP expenses that will be recorded in any period, as it is based upon a valuation model which considers several variables.

Unrealized foreign exchange loss for the three months ended March 31, 2021 was \$9.2 million lower than the same period of 2020. These losses resulted from fluctuations in the exchange rates between the Canadian dollar, U.S. dollar and the Brazilian Real.

Chemtrade has hedged its investment in foreign operations that use the U.S. dollar as their functional currency with its U.S. dollar-denominated long-term debt. As a result, any gains and losses arising from the U.S. dollar-denominated debt will be offset by the foreign currency gain or loss arising from the investment in the foreign operations. The gains and losses on the translation of the designated amount of U.S. dollar-denominated debt and investment in foreign operations are recognized on a net basis in other comprehensive income. For the three months ended March 31, 2021, foreign exchange gain of \$8.6 million on the revaluation of the U.S. dollar-denominated debt and investment in foreign operations was recognized in other comprehensive income, compared with foreign exchange loss of \$54.4 million during the three months ended March 31, 2020.

Reserve for legal proceedings

General Chemical (which was acquired by Chemtrade) was a subject of an investigation by the U.S. Department of Justice concerning alleged anti-competitive conduct in the water treatment chemicals industry, for which General Chemical obtained the benefit of conditional amnesty from criminal charges. General Chemical and Chemtrade were also defendants in class action lawsuits and a few civil proceedings relating to the same conduct. Corporate costs for the year ended December 31, 2019 included an expense of \$40.0 million which increased the reserve for the costs of litigating and resolving all of the civil actions commenced against General Chemical and Chemtrade and various other defendants for anti-competitive actions in the water business.

The main class action civil lawsuit was settled for US\$56.0 million and was paid out during 2019. By the third quarter of 2019, additional settlements were negotiated and paid. The remaining ex-employee initiated derivative actions were settled in March 2021, at close to the amount previously reserved for this matter. The terms of the settlement are subject to finalization and approval by the relevant governmental entities and courts. The reserve for legal proceedings is included as part of provisions and presented as current liabilities in the Condensed Consolidated Interim Statements of Financial Position.

Assets Held For Sale

During the second quarter of 2019, management decided to pursue the sale of two specialty chemicals related assets (potassium chloride and vaccine adjuvants) within the WSSC segment. Accordingly, \$199.5 million (December 31, 2020 - \$199.7 million) of assets, along with \$17.8 million (December 31, 2020 - \$17.0 million) of liabilities directly associated with these assets have been presented as held for sale as at March 31, 2021.

Goodwill Impairment

During the first quarter of 2020, as a result of changes in macro-economic conditions which resulted in a significant increase in discount rates, combined with consideration of historic and forecast performance of each cash-generating unit ("CGU"), Chemtrade performed a test for goodwill impairment for the water solutions groups of CGUs ("CGU group") in WSSC. Although the water solutions CGU group's operating performance had been improving, as a result of applying the higher discount rate, this CGU group's carrying value exceeded its recoverable amount by \$56.0 million and therefore an impairment loss of \$56.0 million was fully allocated to goodwill and recognized in cost of sales and services. Following the impairment recognized in the water solutions CGU group, its recoverable amount equalled its carrying value.

During the first quarter of 2021, there were no indicators of impairment identified; therefore, Chemtrade did not perform a test for goodwill impairment.

Foreign Exchange

Chemtrade has certain operating subsidiaries that use the U.S. dollar as their functional currency. As Chemtrade reports in Canadian dollars, its reported net earnings are exposed to fluctuations in the Canadian/U.S. dollar exchange rate. If the Canadian dollar weakened by one-cent (for example, from \$1.26 to \$1.27), on an unhedged basis, this would have a positive impact on annual net earnings of approximately \$1.1 million, and vice-versa. The impact on annual Adjusted EBITDA and Distributable cash after maintenance capital expenditures would be approximately \$2.3 million and \$1.2 million, respectively, and vice-versa.

The investment in the U.S. dollar-denominated foreign operations has been hedged by Chemtrade's U.S. dollar-denominated credit facilities. Any gains and losses from the translation of U.S. dollar-denominated borrowings on the credit facilities will be offset by the foreign currency gain or loss arising from the investment in the U.S. foreign operations. The gains and losses on the translation of the designated amount of long-term debt and investment in foreign operations are recorded in other comprehensive income. The changes recorded in the accumulated other comprehensive income account since December 31, 2020 were a result of changes in the Canadian/U.S. dollar exchange rate between December 31, 2020 and March 31, 2021.

The rate of exchange used to translate U.S. dollar-denominated balances has decreased from a rate of US\$1.00 = \$1.27 at December 31, 2020 to US\$1.00 = \$1.26 at March 31, 2021. See **Risks and Uncertainties** for additional comments on foreign exchange.

Net Finance Costs

During the three months ended March 31, 2021, net finance costs were \$21.5 million compared with net finance costs of \$67.5 million during the same period of 2020.

Net finance costs were \$46.0 million lower during the first quarter of 2021 relative to 2020. The decrease is primarily due to a \$45.2 million decrease in losses related to a change in the fair value of Debentures.

The Debentures are recognized at fair value with changes in fair value due to changes in the risk free interest rate presented in net finance costs and changes in Chemtrade's own credit risk presented in other comprehensive income rather than net earnings. During the three months ended March 31, 2021, the fair value of the Fund's Debentures increased by \$64.5 million. As a result, Chemtrade recorded a pre-tax loss of \$2.3 million in net finance costs due to a change in the conversion option fair value and passage of time, offset by an increase in the risk free interest rate, and a loss of \$47.9 million, net of tax recovery of \$14.3 million, in other comprehensive income due to a decrease in Chemtrade's own credit risk. During the comparable period of 2020, Chemtrade recorded a pre-tax loss of \$47.4 million in net finance costs due to a decrease in the risk free interest rate, and a gain of \$142.4 million, net of tax expense of \$52.7 million, in other comprehensive income due to an increase in Chemtrade's own credit risk.

The weighted average effective annual interest rate of the Credit Facilities at March 31, 2021 was 4.2% (December 31, 2020 - 4.3%). See **Liquidity and Capital Resources** - *Financing Activities* - *Financial Instruments* for information concerning swap arrangements.

Income Taxes

The Fund is a mutual fund trust and a specified investment flow-through trust ("SIFT") for income tax purposes. The Fund is subject to current income taxes at the top marginal tax rate applicable to individuals of approximately 53.5% on all taxable income not distributed to Unitholders. The Fund is also subject to current income taxes on all taxable income, other than dividends, earned from Canadian corporate and flow-through subsidiaries (other than Canadian subsidiaries that earn certain investment income) at a tax rate similar to the corporate tax rate. The Fund is not subject to tax on income received from non-Canadian subsidiaries, provided that the income is distributed to Unitholders during the year. Based on the current organization of the Fund and its subsidiaries, Chemtrade expects that its income distributed to Unitholders will not be subject to SIFT tax.

Taxable income distributed by the Fund to its Unitholders is considered taxable income of those Unitholders.

Current income tax for the first quarter of 2021 was a recovery of \$0.5 million compared with a current income tax expense of \$0.9 million during the same period of 2020. The decrease of \$1.4 million is primarily due to the reduced Base Erosion and Anti-Abuse Tax ("BEAT tax") as a result of limitations on business interest expense deduction in the U.S. and the deduction of unrealized foreign exchange losses in Brazil.

Deferred income tax recovery for the first quarter of 2021 decreased by \$13.9 million compared with the same period of 2020. The decrease in deferred income tax recovery was primarily due to lower capital losses associated with the fair value changes of the Debentures, a decrease of non-capital losses in Canada, partially offset by an increase in net operating losses in the U.S.

The effective tax rate for the first quarter of 2021 differs from the statutory tax rate primarily due to the deduction of taxable income distributed to Unitholders, differences in domestic corporate and trust tax rates, and certain permanent differences.

During the first quarter of 2021, deferred tax assets increased by \$19.8 million primarily due to the reduction of capital gains associated with the fair value changes of the Debentures, net operating losses and non-deductible interest carryovers recognized in the U.S. During the first quarter of 2021, deferred tax liabilities increased by \$2.7 million primarily due to a decrease of unrealized foreign exchange losses in Brazil.

The Fund does not record deferred taxes related to its deductible temporary differences nor those of its flow-through subsidiaries, as these differences primarily relate to investments in corporate subsidiaries and are expected to reverse without tax consequences to the Fund.

Excess Cash Flows and Net Earnings Over Distributions Paid

The following table presents excess cash flows from operating activities and net earnings over distributions paid for the three months ended March 31, 2021, and for the years ended December 31, 2020 and December 31, 2019.

	<u>Thr</u>	ended ended	Year e	ended
(\$'000)	N	larch 31, 2021	December 31, 2020	December 31, 2019
Cash (used in) flows from operating activities (1)	\$	(6,396)	\$ 270,183	\$ 163,911
Net loss	\$	(20,448)	\$ (167,478)	\$ (99,654)
Cash distributions paid during period	\$	12,157	\$ 66,670	\$ 111,116
(Shortfall) excess of cash flows from operating activities over cash distributions paid	\$	(18,553)	\$ 203,513	\$ 52,795
Shortfall of net loss over cash distributions paid	\$	(32,605)	\$ (234,148)	\$ (210,770)

⁽¹⁾ In 2021, Chemtrade reclassified certain items into net cash flows (used in) from operating activities. Comparatives have been restated to conform to current period presentation.

Chemtrade considers the amount of cash generated by the business in determining the amount of distributions available for payment to its Unitholders. In general, Chemtrade does not take into account quarterly working capital fluctuations as these tend to be temporary in nature. Chemtrade does not generally consider net earnings in setting the level of distributions as this is a non-cash metric and is not reflective of the level of cash flow that Chemtrade can generate. This divergence is particularly relevant for Chemtrade as it has a relatively high level of depreciation and amortization expenses, foreign exchange gains and losses, and deferred tax expenses and recoveries.

Distributions -

On March 11, 2020, Chemtrade announced a reduction of its monthly distributions to \$0.05 per unit.

On July 13, 2020, Chemtrade announced the commencement of a Distribution Reinvestment Plan ("DRIP"). Under the terms of the DRIP, eligible Unitholders may elect to reinvest all or a portion of their regular monthly distributions in additional units of Chemtrade, without paying any commissions, service charges or brokerage fees under the DRIP. Units purchased for participants under the DRIP may be newly issued by Chemtrade from treasury or may be existing units purchased on the open market through the facilities of a stock exchange. Under the DRIP, the Board determines which of these two sources may be used and currently the units are issued from treasury. Currently, the participants receive bonus distributions of Units equal to 3% of the amount of the cash distribution reinvested, as determined by the Board.

Distributions to Unitholders for the three months ended March 31, 2021 were declared as follows:

Record Date	Payment Date		Date Distribution Per Unit (1)	
Three months ended March 31:				
January 29, 2021	February 23, 2021	\$	0.05 \$	4,683
February 26, 2021	March 26, 2021		0.05	4,684
March 31, 2021	April 27, 2021		0.05	5,187
Total for the three months ended March 31, 2021		\$	0.15 \$	14,554

⁽¹⁾ Based on actual number of units outstanding on record date.

Distributions to Unitholders for the three months ended March 31, 2020 were declared as follows:

Record Date	Payment Date		Distribution Payment Date Per Unit (1)		Total (\$'000)
Three months ended March 31:					
January 31, 2020	February 28, 2020	\$	0.10 \$	9,260	
February 28, 2020	March 31, 2020		0.10	9,260	
March 31, 2020	April 30, 2020		0.05	4,630	
Total for the three months ended March 31, 2020		\$	0.25 \$	23,150	

⁽¹⁾ Based on actual number of units outstanding on record date.

Treatment of Chemtrade's distributions for Canadian Income Tax purposes for 2020 and 2021 is as follows:

	Foreign Non-Business				
	Other Income	Dividends ⁽¹⁾	Income	Total	
2020	1.0%	12.0%	87.0%	100%	
2021 ⁽²⁾	0.0%	25.0%	75.0%	100%	

⁽¹⁾ These dividends are not considered to be eligible dividends for Canadian resident Unitholders and therefore not eligible for the enhanced tax credit

Liquidity and Capital Resources

The Fund's distributions to Unitholders are sourced entirely from its investments in operating subsidiary entities. The Fund's investments are financed by trust units held by Unitholders, the Credit Facilities (see *Financing Activities* below), and the Debentures. The cash flow of Chemtrade is required to fund cash distributions to Unitholders, capital requirements, interest, general corporate purposes and other legal obligations.

Cash Flows from (used in) Operating Activities

Cash flows from operating activities for the first quarter of 2021 were an outflow of \$6.4 million, compared with an inflow of \$30.3 million for the same period of 2020. The decrease in cash flow from operating activities of \$36.7 million was primarily due to lower Adjusted EBITDA, changes in working capital, higher interest paid, partially offset by income tax refunds for the first quarter of 2021, compared with income taxes paid during the same period of 2020.

Investing Activities

Capital expenditures were \$8.8 million in the first quarter of 2021, compared with \$11.8 million in the first quarter of 2020. These amounts include \$8.2 million in the first quarter of 2021 and \$11.0 million in the first quarter of 2020 for maintenance capital expenditures. The lower capital expenditures in 2021 compared with the same period of 2020 is due to the COVID-19 pandemic-related restrictions. Chemtrade expects to incur approximately \$75.0 to \$80.0 million of maintenance capital expenditures during 2021.

⁽²⁾ Pursuant to the commencement of the DRIP, distributions declared for the three months ended March 31, 2021 includes bonus distributions.

⁽²⁾ Represents anticipated tax characterization of planned distributions. The actual tax treatment of 2021 distributions will be determined by February 28, 2022.

Non-maintenance capital expenditures were \$0.6 million during the first quarter of 2021, compared with \$0.8 million during the first quarter of 2020. Non-maintenance capital expenditures are: (i) pre-identified or pre-funded, usually as part of a significant acquisition and related financing; (ii) considered to expand or improve the capacity of Chemtrade's operations; (iii) significant environmental capital expenditures that are considered to be non-recurring; or (iv) capital expenditures to be reimbursed by a third party.

Financing Activities

At March 31, 2021, Chemtrade's Credit Facilities were comprised of a \$408.3 million (US\$325.0 million) five year term bank debt and a \$659.5 million (US\$525.0 million) revolving credit facility.

During the second quarter of 2020, Chemtrade modified certain terms of its Credit Facilities including negotiating an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2022 in light of the uncertain economic climate arising from the COVID-19 pandemic. Chemtrade incurred \$1.3 million of transaction costs related to the modification. These costs have been deferred and are being amortized to finance costs in comprehensive income using the effective interest method.

In May 2021, Chemtrade modified certain terms of its Credit Facilities including negotiating an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2023 (see **Recent Developments**).

There was a net decrease in borrowings on the revolving portion of the Credit Facilities of \$26.4 million during the three months ended March 31, 2021 compared with a net increase of \$134.5 million during the same period of 2020. During the three months ended March 31, 2021, Chemtrade used a portion of the proceeds from the equity offering to repay outstanding indebtedness under its Credit Facilities (see **Recent Developments**). During the three months ended March 31, 2020, the additional borrowings on the Credit Facilities were primarily used to redeem the remaining portion of the outstanding CEI Series VI Debentures at a total aggregate redemption price of \$74.6 million.

During the first quarter of 2021, Chemtrade completed an equity offering of 9,800,000 units at a price of \$7.15 per unit, resulting in total gross proceeds of \$70.1 million. Chemtrade incurred issuance costs of \$2.5 million, net of tax recovery of \$1.2 million, which included underwriters' fees and other expenses relating to the offering. Proceeds from the offering were used to repay outstanding indebtedness under Chemtrade's Credit Facilities and for general trust purposes (see **Recent Developments**).

Distributions paid to Unitholders, net of distributions reinvested during the three months ended March 31, 2021 were \$12.2 million, compared to \$27.8 million for the same period of 2020. The decrease is primarily due to the reduction in monthly distributions from \$0.10 per unit to \$0.05 per unit as announced on March 11, 2020 and commencement of the DRIP as announced on July 13, 2020. For additional information on cash distributions, see **Non-IFRS Measures** - *Cash Flow* and **Excess Cash Flows and Net Earnings Over Distributions Paid.**

Financial Instruments -

On April 24, 2020, Chemtrade entered into a swap arrangement which fixed the LIBOR components of its interest rates on up to US\$250.0 million of its outstanding revolving credit under its long term debt until it expired on April 24, 2021. Chemtrade's swaps were formally designated as cash flow hedges at the date of inception and any changes in the fair value of the effective portion of the swaps are recognized in other comprehensive income in the condensed consolidated interim statements of comprehensive income.

During the first quarter of 2021, Chemtrade blended and extended its existing US\$175.0 million and US\$150.0 million interest rate swaps on its outstanding term bank debt. Effective March 24, 2021, the terms of these swaps were extended until October 2024 to align with the maturity date of the term bank debt. Chemtrade recognizes the blend and extend as a termination of the original swaps and execution of new swaps. As a result, hedge accounting on the original swaps were discontinued prospectively. To continue the benefits of hedge accounting, Chemtrade designated the new blend and extend swaps in new hedge relationships. Since the interest payments that are being hedged are still expected to occur, the fair values of the old swaps as of the termination date will remain in accumulated other comprehensive income and reclassified into net earnings over the term of original swaps.

Chemtrade hedges its investment in foreign operations that use the U.S. dollar as their functional currency with its U.S. dollar-denominated long-term debt. Any gains and losses arising from the U.S. dollar-denominated debt will be offset by the foreign currency gain or loss arising from the investment in the foreign operations. The gains and losses on the translation of the designated amount of U.S. dollar-denominated debt and investment in foreign operations are recognized in other comprehensive income.

Cash Balances -

At March 31, 2021, Chemtrade had net cash balances of \$12.0 million and a working capital deficit of \$22.9 million. Comparable figures for December 31, 2020 were \$12.5 million and a working capital deficit of \$62.6 million. The working capital deficit is due to the commencement of the receivables purchase facility ("A/R Facility") during the fourth quarter of 2020. Chemtrade defines working capital to exclude cash, assets held for sale, distributions payable, current portion of long-term debt and Debentures, and liabilities directly associated with assets held for sale. Cash generated by Chemtrade will be used to fund cash distributions to Unitholders, capital requirements, interest, general corporate purposes and other legal obligations.

Future Liquidity -

The future liquidity of Chemtrade is primarily dependent on cash flows of its operating subsidiaries. These cash flows will be used to finance ongoing expenditures, including maintenance capital, distributions to Unitholders and normal course financial commitments. Cash flows are sensitive to changes in volume, sales prices and input costs and any changes in these may impact future liquidity. Management believes that cash flows from operating activities will be sufficient for Chemtrade to meet future obligations and commitments that arise in the normal course of business activities. However, there is inherently more uncertainty associated with the Fund's future operating assumptions given the changing circumstances surrounding the COVID-19 pandemic. See **Risks and Uncertainties** - *Risk of Pandemic* for more details. In addition, Chemtrade has revolving credit facilities which can

be used for general corporate purposes, including to fund capital expenditures. See *Capital Resources* below for more details.

Capital Resources -

At March 31, 2021, Chemtrade had Credit Facilities of approximately \$1.1 billion (US\$850.0 million), consisting of a \$408.3 million (US\$325.0 million) five year term loan and a \$659.5 million (US\$525.0 million) revolving credit facility. At March 31, 2021, Chemtrade had the entire term loan outstanding, and had drawn \$337.0 million on its revolving credit facility. Additionally, it had committed a total of \$18.7 million of its revolving credit facility towards standby letters of credit.

During the second quarter of 2020, Chemtrade modified certain terms of its Credit Facilities including negotiating an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2022 in light of the uncertain economic climate arising from the COVID-19 pandemic. Additionally, in May 2021, Chemtrade negotiated an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2023 (see **Recent Developments**).

At March 31, 2021, Chemtrade had four series of Debentures outstanding with an aggregate par value of \$531.1 million (market value of \$510.4 million) and maturity dates ranging from August 31, 2023 to October 31, 2026.

During the first quarter of 2020, Chemtrade redeemed all of the outstanding CEI Series VI Debentures at a total aggregate redemption price of \$74.6 million being equal to 100% of the principal amount of Debentures outstanding, plus accrued and unpaid interest to, but excluding, the redemption date. This represented a redemption in full of the CEI Series VI Debentures. Chemtrade used its Credit Facilities to fund the redemption.

During the third quarter of 2020, Chemtrade completed a public offering of \$86.3 million principal amount of convertible unsecured subordinated debentures, at a price of \$1,000 per debenture, with an interest rate of 8.50% per annum. Chemtrade incurred transaction costs of \$4.0 million which included underwriters' fees and other expenses relating to the offering.

During the third quarter of 2020, Chemtrade redeemed \$100.0 million principal amount of the outstanding Fund 2014 5.25% Debentures at a total aggregate redemption price of \$101.3 million, being equal to the principal amount of debentures redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. Chemtrade used a portion of the net proceeds from the Fund 2020 8.5% Debentures offering and its Credit Facilities to fund the redemption.

During the fourth quarter of 2020, Chemtrade redeemed the remaining \$26.5 million principal amount of the Fund 2014 5.25% Debentures at a total aggregate redemption price of \$26.9 million, being equal to 100% of the principal amount of debentures outstanding, plus accrued and unpaid interest to, but excluding, the redemption date. This represented a redemption in full of the Fund 2014 5.25% Debentures. Chemtrade used a portion of the net proceeds from the Fund 2020 8.5% Debentures offering, its Credit Facilities and a portion of the proceeds received from its A/R Facility to fund the redemption.

During the first quarter of 2021, Chemtrade completed an equity offering of 9,800,000 units at a price of \$7.15 per unit, resulting in total gross proceeds of \$70.1 million. Chemtrade incurred issuance costs of \$2.5 million, net of tax recovery of \$1.2 million, which included underwriters' fees and other expenses relating to the offering. Proceeds from the offering were used to repay outstanding indebtedness under Chemtrade's Credit Facilities and for general trust purposes (see **Recent Developments**).

Debt Covenants -

As at March 31, 2021, Chemtrade was compliant with all debt covenants contained in its credit agreement.

Summary of Quarterly Results

(\$ millions)	C	1 2021	Q4 2020		Q3 2020	Q2 2020		Q1 2020	(Q4 2019	Q3 2019	Q2 2019
Revenue	\$	312.4	319.4	\$	345.9 \$	347.5	\$	366.9	\$	355.2	\$ 395.6	\$ 396.7
Cost of sales and services		(291.5)	(304.6))	(338.5)	(314.9))	(388.0)		(331.5)	(354.2)	(409.0)
Gross profit (loss)		20.9	14.8		7.4	32.6		(21.1)		23.7	41.4	(12.3)
Selling and administrative expenses:												
Unrealized foreign exchange (loss) gain		(0.4)	1.6		_	7.2		(9.6)		2.7	(1.0)	5.1
LTIP		(5.6)	(9.2))	(2.8)	(0.5))	5.6		(0.4)	(6.0)	(2.3)
Other		(22.5)	(23.8))	(24.4)	(26.0))	(26.5)		(21.7)	(20.7)	(24.2)
Total selling and administrative expenses		(28.5)	(31.4))	(27.2)	(19.3))	(30.5)		(19.4)	(27.7)	(21.4)
Operating (loss) income		(7.5)	(16.6))	(19.8)	13.3		(51.5)		4.3	13.7	(33.7)
Net finance costs:												
Mark-to-market on Debentures		(2.3)	(3.6))	(21.8)	17.0		(47.4)		13.0	(1.5)	(5.0)
Debt issuance and extinguishment costs		_	_		(4.0)	_		_		(4.5)	_	_
Other		(19.2)	(20.4))	(20.3)	(19.7))	(20.1)		(21.0)	(21.2)	(21.2)
Total net finance costs Income tax recovery		(21.5)	(24.0))	(46.1)	(2.7))	(67.5)		(12.5)	(22.7)	(26.2)
(expense)		8.6	14.8		17.6	(6.1))	21.1		(4.4)	8.8	2.3
Net (loss) earnings	\$	(20.4) \$	(25.8)) \$	(48.3) \$	4.5	\$	(97.9)	\$	(12.6)	\$ (0.2)	\$ (57.6)

In general, seasonality has had a limited impact on financial results. Below are some of the key items that had a significant impact on financial results over the last eight quarters.

Revenue and Gross Profit

Gross profit for the first quarter of 2021 was lower due to lower sales volumes of sodium chlorate in the EC segment, reduced demand and lower sales volumes of acid products in the SPPC segment and lower sales volumes of water solutions products in the WSSC segment due to disruptions caused by the severe winter storm experienced in large parts of the U.S. Gross profit for the fourth quarter of 2020 was lower due to lower chlor-alkali sales volumes as a result of the North Vancouver chlor-alkali plant operating at lower rates, as it underwent a biennial maintenance turnaround. Also, there was reduced demand and lower sales volumes for products in the

SPPC segment resulting from the COVID-19 pandemic. Gross profit for the third quarter of 2020 was lower due to a \$19.8 million write-down of assets primarily as a result of the decision to rationalize sulphuric acid capacity. During the first quarter of 2020, goodwill impairment of \$56.0 million related to certain water solutions products was recorded. Gross profit for the fourth quarter of 2019 was lower due to significantly lower selling prices for caustic soda. During the second quarter of 2019, gross profit was lower due to goodwill impairment of \$65.6 million related to certain specialty chemical products.

Selling and Administrative Expenses

The change in fair value of Chemtrade's LTIP obligation is included in selling and administrative expenses. The amount of the expense recorded in any quarter depends on changes in the various factors used in arriving at the fair value of the obligation.

Net Finance Costs

Net finance costs include changes in the fair value of the Debentures. The amount recorded in any quarter related to the fair value adjustments on the Debentures fluctuates depending upon the market value of the Debentures at the end of the period. The primary component of other net finance costs is interest from Chemtrade's Credit Facilities and Debentures.

Net finance costs for the third quarter of 2020 included \$4.0 million of transaction costs on the issuance of Debentures. The fourth quarter of 2019 included \$4.5 million of transaction costs on the issuance of Debentures.

Outstanding Securities of the Fund

As at May 7, 2021 and March 31, 2021, the following units and securities convertible into units of the Fund were issued and outstanding:

	May 7, 20	21	March 31, 2	021		
	Convertible Securities	Units	Convertible Securities	Units		
Units outstanding		103,357,789		103,236,649		
5.00% Debentures (1)	143,750	5,784,708	143,750	5,784,708		
4.75% Debentures (2)	201,115	7,532,397	201,115	7,532,397		
6.50% Debentures (3)	100,000	6,329,114	100,000	6,329,114		
8.50% Debentures (4)	86,250	11,734,694	86,250	11,734,694		
Units outstanding and issuable upon conversion of Debentures		134,738,702		134,617,562		
Deferred units plan (5)(6)	\$ 4,378	523,679	\$ 3,567	519,967		
Units outstanding and issuable upon conversion of Debentures and Deferred units		135,262,381		135,137,529		

⁽¹⁾ Convertible at \$24.85 per unit

⁽²⁾ Convertible at \$26.70 per unit

⁽³⁾ Convertible at \$15.80 per unit

⁽⁴⁾ Convertible at \$7.35 per unit

⁽⁵⁾ Based on \$8.36 and \$6.86, the closing price of a unit on the TSX on May 7, 2021 and March 31, 2021 respectively

^{(6) 476,321} and 480,033 deferred units were available for future grants as at May 7, 2021 and March 31, 2021 respectively

Contractual Obligations

Information concerning contractual obligations at March 31, 2021 is shown below:

Contractual Obligations (\$'000)	Total	Less Than 1 Year	1-3 Years	4-5 Years	After 5 Years
Long-term debt	\$ 745,264 \$	— \$	— \$	745,264 \$	_
Debentures	531,115	_	143,750	287,365	100,000
Purchase commitments	80,596	26,632	28,781	25,183	_
Interest on Debentures	117,020	30,572	56,969	25,650	3,829
Interest on long-term debt	111,844	31,330	62,660	17,854	_
Lease payments	171,276	50,798	69,930	29,012	21,536
Total contractual obligations	\$ 1,757,115 \$	139,332 \$	362,090 \$	1,130,328 \$	125,365

Risks and Uncertainties

Chemtrade operates a diversified business providing industrial chemicals and services to customers in North America and around the world. Chemtrade is one of North America's largest suppliers of sulphuric acid, spent acid processing services, inorganic coagulants for water treatment, sodium chlorate, sodium nitrite, sodium hydrosulphite and phosphorus pentasulphide. Chemtrade is a leading regional supplier of sulphur, chlor-alkali products, liquid sulphur dioxide, potassium chloride, and zinc oxide. Additionally, Chemtrade provides industrial services such as processing by-products and waste streams. Chemtrade faces various risks associated with its business. These risks include, amongst others, a general reduction in demand for its products, the loss of a portion of its customer base, the interruption of the supply of products or raw materials, price fluctuations in the products sold and/or raw materials purchased, industry capacity, acquisition integration and operational, transportation and product hazard risks associated with the nature of its business. Chemtrade imports key raw materials and products from overseas and as such has additional risks associated with the sourcing activity. Chemtrade makes extensive use of the railway system to transport material within North America. Certain locations are serviced by a sole carrier and thus a disruption in service or changes to the regulatory environment relating to transportation could have a significant negative impact on results. In addition, Chemtrade sells a significant portion of its major products to large customers. While many of these customers are under contract, there can be no assurance that these contracts will be renewed. As Chemtrade's business is international in nature, it is exposed to foreign exchange risks related to the payment of dividends and other transactions by its foreign subsidiaries. For a more detailed discussion of Chemtrade's risks, please refer to the "RISK FACTORS" section of the most recently filed Annual Information Form.

Chemtrade manages the risks associated with its customer base and sales prices by seeking to obtain contractual protection to mitigate these risks. Chemtrade also seeks to differentiate its products and services with customers to mitigate price fluctuations and uses its scale to obtain beneficial raw material contracts.

Chemtrade's Board periodically reviews a framework identifying the principal risks of Chemtrade's business, and ensures the implementation of appropriate systems to manage these risks. The Audit Committee reviews major financial risks, the systems implemented to monitor those risks and the strategies in place to manage those risks. Chemtrade's Responsible Care Committee reviews major operational risks, the systems implemented to monitor

those risks and the strategies in place to manage those risks. In addition, Chemtrade maintains an extensive insurance program which includes general liability and environmental coverage.

There are a number of risks that warrant additional disclosure which are discussed in detail in the MD&A for the year ended December 31, 2020. There have been no material changes to the business of Chemtrade that require an update to the discussion of these risks except as noted below.

Interest rate risk

Chemtrade has a credit facility with long-term debt and operating lines of credit which bear variable rates of interest. As at March 31, 2021, on an unhedged basis, a change in interest rates of 1% per annum would have an impact of approximately \$7.5 million on Chemtrade's net earnings per annum. As at March 31, 2021, Chemtrade had fixed interest rates on 96.9% of its senior debt until April 2021 and 54.8% thereafter until October 2024.

Managing interest rate benchmark reform and associated risks

A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some interbank offered rates (IBORs) with alternative nearly risk-free rates ("RFR"). Chemtrade has exposures to IBORs on its financial instruments that will be replaced or reformed as part of these market-wide initiatives. There is uncertainty over the timing and the methods of transition in some jurisdictions that Chemtrade operates in.

The IBOR reform has an impact on Chemtrade's operational and risk management processes and hedge accounting. The main risks to which Chemtrade is exposed as a result of IBOR reform are operational. For example, renegotiating borrowing contracts through bilateral negotiation with counterparties, implementing new fallback clauses with its derivative counterparties, updating contractual terms and revising operational controls related to the reform. Financial risk is predominantly limited to interest rate risk. Hedging relationships may experience ineffectiveness due to uncertainty about when and how replacement may occur with respect to the relevant hedged item and hedging instrument or the difference in the timing of a replacement.

Chemtrade monitors the progress of transition from IBORs to new benchmark rates by reviewing the total amounts of contracts that have yet to transition to an alternative benchmark rate and the amounts of such contracts that include an appropriate fallback clause. Chemtrade considers that a contract is not yet transitioned to an alternative benchmark rate when interest under the contract is indexed to a benchmark rate that is still subject to IBOR reform, even if it includes a fallback clause that deals with the cessation of the existing IBOR (referred to as an 'unreformed contract').

Derivatives

Chemtrade holds interest rate swaps for risk management purposes which are designated in cash flow hedging relationships. The interest rate swaps have floating legs that are indexed to 1-month LIBOR. Chemtrade's derivative instruments are governed by contracts based on the International Swaps and Derivatives Association (ISDA)'s master agreements.

ISDA is currently reviewing its standardized contracts in the IBOR reform and plans to amend certain floating-rate options in the 2006 ISDA definitions to include fallback clauses that would apply on the permanent discontinuation of certain key IBORs. ISDA is expected to publish an IBOR fallback supplement to amend the 2006 ISDA definitions and an IBOR fallback protocol to facilitate multilateral amendments to include the amended floating-rate options in derivative transactions that were entered into before the date of the supplement. Chemtrade will adhere to the protocol if and when it is finalized and monitor whether its counterparties will adhere. If this plan changes or there are counterparties who will not adhere to the protocol, Chemtrade will negotiate with them bilaterally about including new fallback clauses.

Hedge accounting

Chemtrade's hedged items and hedging instruments continue to be indexed to 1-month LIBOR. These benchmark rates are quoted each day and the IBOR cash flows are exchanged with counterparties as usual.

Chemtrade's exposure to 1-month LIBOR designated in hedging relationships is US\$575.0 million nominal amount at March 31, 2021, representing both the nominal amount of the hedging interest rate swap and the principal amount of the hedged USD denominated secured bank loan liability maturing in October 2024. Of the US\$575.0 million nominal amount outstanding at March 31, 2021, US\$250.0 million relating to the hedge on the revolving credit facility expired on April 24, 2021.

The IBOR reform had no impact on the interim condensed consolidated financial statements of Chemtrade. Chemtrade intends to use the RFR for its risk management and hedge accounting in future periods if it becomes applicable. Chemtrade will actively monitor the IBOR reform and consider circumstances as it becomes party to new or revised interest rate swaps.

Significant Judgments and Sources of Estimation Uncertainty

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Significant judgments

Information about judgements that have a significant risk of resulting in a material adjustment within the next financial year are discussed in detail in the MD&A for the year ended December 31, 2020. There have been no material changes to the business of Chemtrade that require an update to the discussion of these significant judgements.

Key sources of estimation uncertainty

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year are discussed in detail in the MD&A for the year ended December 31, 2020. There have been no material changes to the business of Chemtrade that require an update to the discussion of these sources of estimation uncertainty.

Standards and interpretations adopted during the period

Interest Rate Benchmark reform ("IBOR reform") – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)

Chemtrade has initially adopted IBOR reform - Phase 2 - Amendments to IFRS 9, *Financial Instruments* ("IFRS 9"), IAS 39, *Financial Instruments: Recognition and Measurement* ("IAS 39"), IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"), IFRS 4, *Insurance Contracts* ("IFRS 4") and IFRS 16, *Leases* ("IFRS 16") (the "Phase 2 amendments") from January 1, 2021.

Chemtrade applied the Phase 2 amendments retrospectively. However, in accordance with the exceptions permitted in the Phase 2 amendments, Chemtrade has elected not to restate the prior period to reflect the application of these amendments, including not providing additional disclosures for 2020. There is no impact on opening unitholders' equity balances as a result of retrospective application.

Specific policies applicable from 1 January 2021 for IBOR reform

The Phase 2 amendments provide practical relief from certain requirements in IFRS Standards. These reliefs relate to modifications of financial instruments and lease contracts or hedging relationships triggered by a replacement of a benchmark interest rate in a contract with a new alternative benchmark rate.

If the basis for determining the contractual cash flows of a financial asset or financial liability measured at amortised cost changes as a result of IBOR reform, then Chemtrade updates the effective interest rate of the financial asset or financial liability to reflect the change that is required by the reform. A change in the basis for determining the contractual cash flows is required by IBOR reform if the following conditions are met:

- · the change is necessary as a direct consequence of the reform; and
- the new basis for determining the contractual cash flows is economically equivalent to the previous basis –
 i.e. the basis immediately before the change.

If changes are made to a financial asset or financial liability in addition to changes to the basis for determining the contractual cash flows required by IBOR reform, then Chemtrade first updates the effective interest rate of the financial asset or financial liability to reflect the change that is required by IBOR reform. Subsequently, Chemtrade applies the policies on accounting for modifications set out above to the additional changes.

The amendments also provide an exception to use a revised discount rate that reflects the change in interest rate when remeasuring a lease liability because of a lease modification that is required by IBOR reform.

Finally, the Phase 2 amendments provide a series of temporary exceptions from certain hedge accounting requirements when a change required by IBOR reform occurs to a hedged item and/or hedging instrument that permit the hedge relationship to be continued without interruption. Chemtrade applies the following reliefs as and when uncertainty arising from IBOR reform is no longer present with respect to the timing and the amount of the IBOR-based cash flows of the hedged item or hedging instrument:

- Chemtrade amends the designation of a hedging relationship to reflect changes that are required by the reform without discontinuing the hedging relationship; and
- when a hedged item in a cash flow hedge is amended to reflect the changes that are required by the reform, the amount accumulated in the cash flow hedge reserve is deemed to be based on the alternative benchmark rate on which the hedged future cash flows are determined.

While uncertainty persists in the timing or amount of the IBOR-based cash flows of the hedged item or hedging instrument, Chemtrade continues to apply the existing accounting policies.

These amendments had no impact on the interim condensed consolidated financial statements of Chemtrade. Chemtrade intends to use the practical expedients in future periods if they become applicable. Chemtrade will actively monitor the IBOR reform and consider circumstances as it becomes party to new or revised financial instruments.

Disclosure Controls and Procedures and Internal Controls Over Financial Reporting

Chemtrade maintains a set of disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that the Fund publicly files is recorded, processed, summarized and reported within a timely manner and that such information is accumulated and communicated to Chemtrade's Management, including its CEO and Chief Financial Officer ("CFO"), as appropriate, to allow timely decisions regarding disclosure. The CEO and the CFO have evaluated Chemtrade's disclosure controls procedures as of March 31, 2021 through inquiry and review. The CEO and the CFO have concluded that, as at March 31, 2021, Chemtrade's design and implementation of the controls were effective.

Chemtrade also maintains a system of internal controls over financial reporting designed under the supervision of Chemtrade's CEO and CFO to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

Chemtrade's Management, including the CEO and the CFO, is responsible for establishing and maintaining adequate internal control over financial reporting and evaluating its effectiveness. Management has used The Committee of Sponsoring Organizations of the Treadway Commission ("COSO") framework (2013) to evaluate the effectiveness of Chemtrade's internal control over financial reporting as of March 31, 2021. There have been no changes to the design of internal controls over financial reporting that occurred during the three months ended March 31, 2021 that have materially affected or are reasonably likely to materially affect the internal controls over financial reporting.

Financial Outlook

The economic uncertainty caused by COVID-19 prevents us from knowledgeably predicting the key elements necessary to make Guidance meaningful. We are therefore unable to provide a definitive Guidance range for 2021, although we can comment on certain key items that are expected to affect our earnings, while cautioning that this is a very fluid situation and that some of our comments below are based largely on input from our customer base which can, and likely will, change over time. Chemtrade intends to reinstate guidance when the economic environment normalizes and Chemtrade's visibility into the future improves.

Accordingly, the following comments should be read with extreme care and we will not update these comments until our next MD&A. Comments on certain key elements that are likely to contribute to Chemtrade's 2021 earnings are as follows:

Key Facilities

We expect all of our key facilities to operate well during the year. We expect normal turnaround activity, with no atypical turnarounds planned, whereas in 2020, we had a significant maintenance turnaround at one of our Regen acid plants. The plant is tied to a once every five-year major maintenance turnaround at this plant's refinery customer. During 2020, our North Vancouver chlor-alkali facility also had its biennial turnaround.

Demand

As a general statement, while COVID-19 is expected to continue affecting demand for certain of our products in 2021, other products have not been affected. For the products affected, the depth and duration largely depends on COVID-19's effect on industrial activity, North American driving miles and the extent of people working from home. In aggregate, sales volumes in 2021 are expected to be higher than 2020.

Certain more specific comments are as follows.

WSSC -

Demand for our Water Solutions business should be similar to 2020 and largely unaffected by COVID-19.
 The industry is however seeing significant increases in the cost of raw materials, particularly in sulphuric acid due to rising costs for Sulphur. In the short-term, spikes in raw materials can result in reduced margins

as it takes some time to pass these on to customers. We are confident in our ability to eventually pass these on to customers.

SPPC -

- We expect full year refinery utilization rates to be higher than 2020, but still be approximately 10% lower than pre-pandemic levels. Demand in the West Coast of the U.S. at the beginning of 2021 was negatively affected by the California stay-at-home orders. Recently, we are seeing signs that as the COVID-19 vaccines are being widely distributed, demand for gasoline is increasing and we expect this to continue as the year progresses.
- During 2021, we anticipate reduced demand for ultrapure acid, which mainly services the semi-conductor industry. One of our large end-use customers decided to obtain acid from an alternate source. We have gained product approval and new business at another of our large customers and have recently begun resupplying product to the customer who stopped buying from us earlier in the year. The new business has significant potential, but will not be sufficient to offset the lost volume in the short-term. We believe demand for ultrapure acid will continue growing in the U.S. and the mid to long term outlook for ultrapure acid remains very positive for us. We are actively pursuing new business, including placing additional volume with existing customers. However, given the nature of this product and stringent quality specification it will take time to fully replace the lost volume.
- Merchant acid volume should be similar to 2020 levels.

EC -

- The North Vancouver chlor-alkali plant is expected to operate at a higher level than 2020, when we had the biennial maintenance turnaround. Recently we have seen an increase in both HCl and chlorine demand. We expect fracking activity particularly for gas in Western Canada to be higher than 2020 which will require more HCl. However, the positive margin effect of the higher caustic and HCl volume is expected to be offset by our current expectation for caustic pricing. We expect that for the full year, the North East Asia spot index for caustic will be lower than 2020. The index is expected to appreciate during the year and end the year significantly higher than the start, however, given that our prices typically lag the index by a quarter the average price realized during 2021 is expected to be lower than 2020. Furthermore, the strong Canadian dollar dilutes the increasing spot prices which are U.S. dollar denominated.
- Finally, aggregate sodium chlorate demand should be higher than 2020, but is expected to be lower than historic levels. Demand will be affected by the extent people working from home during the pandemic reduces paper demand and thus bleached pulp production. Given our current customer mix, we expect our sales volumes in 2021 to be lower than 2020. We have two pulp mill customers who have shut-down over the past six months. We expect realized selling prices in 2021 to be lower than 2020 due to the expectations of a stronger Canadian dollar relative to the US dollar. Over time, we expect to recover the impact of the currency as well as rising costs of production.

Based on the above, the key assumptions in the EC segment are as follows:

- We expect that North American MECU production volumes for 2021 will be approximately 190,000 MECU, limited primarily by demand for our chlorine and HCl products. If demand for these products increases, our production will increase and conversely if demand decreases.
- We expect that the 2021 average North East Asia spot price for caustic soda will be US\$20 per metric tonne
 lower than 2020.
- North American production volume of sodium chlorate for 2021 will be approximately 365,000 metric tonnes.

Chemtrade also expects:

- Maintenance Capital Expenditures to range between \$75.0 million and \$80.0 million;
- Lease Payments to range between \$55.0 million and \$60.0 million.
- Cash Interest (excluding the impact of IFRS 16) to range between \$70.0 million and \$75.0 million.
- Cash Taxes to range between \$5.0 million and \$10.0 million.

Other

Additional information concerning Chemtrade, including the Annual Information Form, is filed on SEDAR and can be accessed at www.sedar.com.

May 10, 2021

Condensed Consolidated Interim Financial Statements of

CHEMTRADE LOGISTICS INCOME FUND

Three months ended March 31, 2021 and 2020 (Unaudited)

Condensed Consolidated Interim Statements of Financial Position (In thousands of Canadian dollars) (Unaudited)

	Notes	March 31, 2021	December 31, 2020
ASSETS			
Current assets			
Cash and cash equivalents	\$	11,978	\$ 12,511
Trade and other receivables		102,378	86,259
Inventories		108,928	111,536
Income taxes receivable		4,097	5,372
Prepaid expenses and other assets		4,945	7,605
Assets held for sale	4	199,464	199,739
Total current assets		431,790	423,022
Non-current assets			
Property, plant and equipment		1,002,110	1,050,307
Right-of-use assets		145,632	151,923
Other assets		6,643	7,022
Intangible assets	8	727,746	748,070
Deferred tax assets	14	139,753	119,982
Total non-current assets		2,021,884	2,077,304
Total assets	\$	2,453,674	\$ 2,500,326
LIABILITIES AND UNITHOLDERS' EQUITY			
Current liabilities			
Trade and other payables	\$	178,568	\$ 207,948
Distributions payable		5,187	4,677
Provisions	11	18,042	17,880
Lease liabilities		46,589	47,501
Liabilities directly associated with assets held for sale	4	17,847	17,049
Total current liabilities	_	266,233	295,055
Non-current liabilities		200,200	200,000
Long-term debt	5	741,205	776,914
Convertible unsecured subordinated debentures	6	510,352	445,895
Other long-term liabilities	·	35,183	40,915
Long-term lease liabilities		107,177	113,982
Employee benefits		30,145	51,363
Provisions		141,275	156,958
Deferred tax liabilities	14	16,081	13,429
Total non-current liabilities		1,581,418	1,599,456
Total liabilities		1,847,651	1,894,511
Unitholders' equity		1,011,001	1,001,011
Units	7	1,534,502	1,465,029
Contributed surplus	=	9,720	9,720
Deficit		(1,122,298)	(1,101,455
Accumulated other comprehensive income		184,099	232,521
Total unitholders' equity		606,023	605,815
Total liabilities and unitholders' equity	\$	2,453,674	\$ 2,500,326

For subsequent events, see Note 18.

Condensed Consolidated Interim Statements of Comprehensive Income (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

		Three months en	ded March 31,
	Notes	2021	2020
Revenue	10	\$ 312,440 \$	366,901
Cost of sales and services	8,13	(291,511)	(387,957)
Gross profit (loss)		20,929	(21,056)
Selling and administrative expenses	11	(28,475)	(30,488)
Operating loss		(7,546)	(51,544)
Net finance costs	12	(21,498)	(67,452)
Loss before income tax		(29,044)	(118,996)
Income tax recovery (expense)	14		
Current		512	(901)
Deferred		8,084	22,022
		8,596	21,121
Net loss		\$ (20,448) \$	(97,875)
Other comprehensive income (loss)			
Items that may subsequently be reclassified to earnings:			
Gain (loss) on net investment hedge of foreign operations, net of tax expense of \$1,107 (2020 - recovery of \$636)	5,15	7,479	(53,756)
Foreign currency translation differences for foreign operations	•	(11,039)	83,925
Effective portion of change in the fair value of cash			
flow hedges, net of tax expense of \$1,065 (2020 - recovery of \$5,833)		3,066	(14,312)
Items that will not be reclassified to earnings:			
Defined benefit plan adjustments, net of tax expense of \$4,656 (2020 - recovery of \$717)		14,159	(3,024)
Change in fair value of convertible debentures due to credit risk, net of tax recovery of \$14,273 (2020 - expense of \$52,718)	6	(47,928)	142,400
Other comprehensive (loss) income		(34,263)	155,233
Total comprehensive (loss) income		\$ (54,711) \$	57,358
Net loss per unit	7		
Basic net loss per unit		\$ (0.21) \$	(1.06)
Diluted net loss per unit		\$ (0.21) \$	(1.06)

Condensed Consolidated Interim Statements of Changes in Unitholders' Equity (In thousands of Canadian dollars) (Unaudited)

			•	No orderly ordered		Cumulative		Jnrealized (gains) losses on cash flow and net	fa	Change in air value of convertible debentures		Total
	Notes	Units	C	Contributed surplus	Deficit	translation account*	ır	hedges*	αι	ue to credit risk*	un	equity
Balance at January 1, 2021		\$ 1,465,029	\$	9,720 \$	(1,101,455)	\$ 160,953	\$	(12,700)	\$	84,268	\$	605,815
Issuance of units for cash, net of transaction costs	7	67,586		_	_	_		_		_		67,586
Issuance of units under the Distribution Reinvestment Plan ("DRIP")	7	1,887		_	_	_		_		_		1,887
Net loss		_			(20,448)	_		_		_		(20,448)
Other comprehensive income (loss)		_		_	14,159	(11,039)		10,545		(47,928)		(34,263)
Distributions	7	_		_	(14,554)	_		_		_		(14,554)
Balance at March 31, 2021		\$ 1,534,502	\$	9,720 \$	(1,122,298)	\$ 149,914	\$	(2,155)	\$	36,340	\$	606,023

	Notes	Units	Contributed surplus	Deficit	_	Cumulative translation account*	Jnrealized gains on cash flow and net nvestment hedges*	fai co de	Change in ir value of onvertible ebentures to credit risk*	un	Total nitholders' equity
Balance at January 1, 2020		\$ 1,462,116	\$ 9,720 \$	(870,874)	\$	171,893	\$ (17,381)	\$	4,102	\$	759,576
Net loss		_	_	(97,875)		_	_		_		(97,875)
Other comprehensive (loss) income		_	_	(3,024)		83,925	(68,068)		142,400		155,233
Distributions	7	_	_	(23,150)		_	_		_		(23,150)
Balance at March 31, 2020		\$ 1,462,116	\$ 9,720 \$	(994,923)	\$	255,818	\$ (85,449)	\$	146,502	\$	(793,784)

^{*} Accumulated other comprehensive income.

Condensed Consolidated Interim Statements of Cash Flows (In thousands of Canadian dollars) (Unaudited)

		Three months en	ded March 31,
	Notes	2021	2020
Cash flows from operating activities:			
Net loss	\$	(20,448) \$	(97,875)
Adjustments for:	•	(==, : :=) +	(0.,0.0)
Depreciation and amortization	13	62,393	63,917
Net loss (gain) on disposal and write-down of property, plant and equipment		151	(482)
Impairment of goodwill	8	_	56,000
Change in environmental liability		_	3,381
Income tax recovery		(8,596)	(21,121)
Net finance costs	12	21,498	67,452
Unrealized foreign exchange loss	11	430	9,608
		55,428	80,880
Increase in working capital	17	(45,942)	(37,761)
Interest paid		(17,202)	(12,787)
Interest received		225	92
Net income tax refunded (paid)		1,095	(103)
Net cash flows (used in) from operating activities		(6,396)	30,321
Cash flows from investing activities:			
Additions to property, plant and equipment		(8,769)	(11,789)
Net cash flows used in investing activities		(8,769)	(11,789)
Cash flows from financing activities:			
Distributions to unitholders, net of distributions	7	(40.457)	(07.700)
reinvested	7	(12,157)	(27,780)
Issuance of units	7	70,070	_
Unit issuance costs	7	(3,672)	_
Repayment of lease liability net of sub-lease receipts		(13,028)	(13,795)
Repayment of convertible debentures	6	_	(74,584)
Net change in revolving credit facility	5	(26,445)	134,502
Net cash flows from financing activities		14,768	18,343
(Decrease) increase in cash and cash equivalents		(397)	36,875
Cash and cash equivalents, beginning of the period		12,511	13,466
Effect of exchange rates on cash held in foreign currencies		(136)	1,837
Cash and cash equivalents, end of the period	\$	11,978 \$	52,178

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

1. CORPORATE INFORMATION:

Chemtrade Logistics Income Fund (the "Fund") is a publicly listed Income Trust formed in Ontario, Canada and its units are listed on the Toronto Stock Exchange ("TSX"). The term "Chemtrade" refers to the Fund and its consolidated subsidiaries. Chemtrade commenced operations on July 18, 2001 when it completed an initial public offering. Chemtrade operates in four reportable segments: Sulphur Products & Performance Chemicals ("SPPC"), Water Solutions & Specialty Chemicals ("WSSC"), Electrochemicals ("EC") and Corporate ("Corp"). For additional information regarding Chemtrade's reportable segments, see note 16.

Chemtrade is an entity domiciled in Canada. The head office, principal address, and registered and records office of the Fund are located at 155 Gordon Baker Road, Suite 300, Toronto, Ontario, M2H 3N5.

Chemtrade's financial statements include all of its controlled subsidiaries and have been prepared on a going concern basis, which contemplates the realization of assets and settlements of liabilities in the normal course of business.

2. BASIS OF PREPARATION:

(a) Statement of compliance:

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting, using the same accounting policies and standards as were used for Chemtrade's 2020 annual consolidated financial statements, except as discussed in note 3. Certain amendments and interpretations apply for the first time in 2021, but do not have an impact on these condensed consolidated interim financial statements.

These condensed consolidated interim financial statements should be read in conjunction with Chemtrade's 2020 annual consolidated financial statements.

The condensed consolidated interim financial statements were authorized for issue by the Board of Trustees (the "Board") on May 10, 2021.

(b) Basis of measurement:

The condensed consolidated interim financial statements have been prepared on the historical cost basis, except for the following material items in the condensed consolidated interim statements of financial position:

Derivative financial instruments are measured at fair value;

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

2. **BASIS OF PREPARATION (continued):**

- Convertible unsecured subordinated debentures are measured at fair value;
- · Liabilities for cash settled share-based payment arrangements are measured at fair value;
- · The defined benefit liability is recognized as the present value of the defined benefit obligation net of the fair value of the plan assets; and
- Deferred tax assets and liabilities are measured at the tax rates that are expected to be applied to temporary differences when they reverse.

(c) Presentation currency:

These condensed consolidated interim financial statements are presented in thousands of Canadian dollars, except for net loss per unit information which is presented in Canadian dollars.

3. SIGNIFICANT ACCOUNTING POLICIES:

Standards and interpretations adopted during the period:

Interest Rate Benchmark Reform ("IBOR reform") - Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16)

Chemtrade has initially adopted IBOR reform - Phase 2 - Amendments to IFRS 9, Financial Instruments ("IFRS 9"), IAS 39, Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 7. Financial Instruments: Disclosures ("IFRS 7"). IFRS 4. Insurance Contracts ("IFRS 4") and IFRS 16, Leases ("IFRS 16") (the "Phase 2 amendments") from January 1, 2021.

Chemtrade applied the Phase 2 amendments retrospectively. However, in accordance with the exceptions permitted in the Phase 2 amendments, Chemtrade has elected not to restate the prior period to reflect the application of these amendments, including not providing additional disclosures for 2020. There is no impact on opening unitholders' equity balances as a result of retrospective application.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

Specific policies applicable from 1 January 2021 for IBOR reform

The Phase 2 amendments provide practical relief from certain requirements in IFRS Standards. These reliefs relate to modifications of financial instruments and lease contracts or hedging relationships triggered by a replacement of a benchmark interest rate in a contract with a new alternative benchmark rate.

If the basis for determining the contractual cash flows of a financial asset or financial liability measured at amortised cost changes as a result of IBOR reform, then Chemtrade updates the effective interest rate of the financial asset or financial liability to reflect the change that is required by the reform. A change in the basis for determining the contractual cash flows is required by IBOR reform if the following conditions are met:

- the change is necessary as a direct consequence of the reform; and
- the new basis for determining the contractual cash flows is economically equivalent to the previous basis i.e. the basis immediately before the change.

If changes are made to a financial asset or financial liability in addition to changes to the basis for determining the contractual cash flows required by IBOR reform, then Chemtrade first updates the effective interest rate of the financial asset or financial liability to reflect the change that is required by IBOR reform. Subsequently, Chemtrade applies the policies on accounting for modifications set out above to the additional changes.

The amendments also provide an exception to use a revised discount rate that reflects the change in interest rate when remeasuring a lease liability because of a lease modification that is required by IBOR reform.

Finally, the Phase 2 amendments provide a series of temporary exceptions from certain hedge accounting requirements when a change required by IBOR reform occurs to a hedged item and/or hedging instrument that permit the hedge relationship to be continued without interruption. Chemtrade applies the following reliefs as and when uncertainty arising from IBOR reform is no longer present with respect to the timing and the amount of the IBOR-based cash flows of the hedged item or hedging instrument:

- Chemtrade amends the designation of a hedging relationship to reflect changes that are required by the reform without discontinuing the hedging relationship; and
- when a hedged item in a cash flow hedge is amended to reflect the changes that are required by the reform, the amount accumulated in the cash flow hedge reserve is

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

deemed to be based on the alternative benchmark rate on which the hedged future cash flows are determined.

While uncertainty persists in the timing or amount of the IBOR-based cash flows of the hedged item or hedging instrument, Chemtrade continues to apply the existing accounting policies.

These amendments had no impact on the interim condensed consolidated financial statements of Chemtrade. Chemtrade intends to use the practical expedients in future periods if they become applicable. Chemtrade will actively monitor the IBOR reform and consider circumstances as it becomes party to new or revised financial instruments.

4. ASSETS HELD FOR SALE:

During 2019, management decided to pursue the sale of two specialty chemicals related assets (potassium chloride and vaccine adjuvants) within the WSSC segment. Accordingly, these assets have been presented as assets held for sale.

The following are details regarding the assets held for sale and the associated liabilities as at March 31, 2021 and December 31, 2020:

Assets held for sale	March 31, 2021	December 31, 2020
Trade and other receivables	\$ 9,624	\$ 7,762
Inventories	6,767	7,045
Prepaid expenses and other assets	90	105
Property, plant and equipment ("PPE")	56,696	56,902
Right of-use ("ROU") assets	123	124
Intangible assets	126,164	127,801
Total	\$ 199,464	\$ 199,739
Liabilities directly associated with assets held for sale		
Trade and other payables	\$ 3,212	\$ 3,124
Lease liabilities	107	130
Deferred tax liabilities	14,528	13,795
Total	\$ 17,847	\$ 17,049

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

5. LONG-TERM DEBT:

Changes in long-term debt are as follows:

	Term bank debt (US\$ denominated)	(US	Revolving credit S\$ denominated) ⁽¹⁾	(C	Revolving credit Cdn\$ denominated) ⁽¹⁾	Trans	action costs	Total
Maturity	October 24, 2024		October 24, 2024		October 24, 2024			
Credit limit US\$ (2)	325,000		525,000					850,000
Drawn US\$	325,000		237,068					562,068
Balance at January 1, 2021	\$ 413,563	\$	328,692	\$	39,000	\$	(4,341)	\$776,914
Net change	_		(26,639)		194		_	(26,445)
Gain on net investment hedge of foreign operations	(5,298)		(3,288)		_		_	(8,586)
Foreign exchange rate changes	_		(960)		_		_	(960)
Accretion expense on financing transaction costs	_		_		_		282	282
Balance at March 31, 2021	\$ 408,265	\$	297,805	\$	39,194	\$	(4,059)	\$741,205

⁽¹⁾ At March 31, 2021, Chemtrade had committed a total of \$18,660 of the revolving credit facility towards standby letters of credit.

⁽²⁾ At March 31, 2021, Cdn\$ limit of the senior credit facilities ("Credit Facilities") was \$1,067,770, consisting of a term bank debt of \$408,265 and a revolving credit facility of \$659,505.

	Term bank debt (US\$ denominated)		Revolving credit (Cdn\$ denominated) ⁽¹⁾	Transaction costs	Total
Maturity	October 24, 2024	October 24, 2024	October 24, 2024		
Credit limit US\$ (2)	325,000	525,000			850,000
Drawn US\$	325,000	313,000			638,000
Balance at January 1, 2020	\$ 421,948	\$ 318,601	\$ 7,724	\$ (3,999)	\$744,274
Net change	_	90,226	44,276	_	134,502
Gain on net investment hedge of foreign operations	35,067	19,325	_	_	54,392
Foreign exchange rate changes	_	11,988	_	_	11,988
Accretion expense on financing transaction costs	_	_	_	185	185
Balance at March 31, 2020	\$ 457,015	\$ 440,140	\$ 52,000	\$ (3,814)	\$945,341

⁽¹⁾ At March 31, 2020, Chemtrade had committed a total of \$11,309 of the revolving credit facility towards standby letters of credit.

⁽²⁾ At March 31, 2020, Cdn\$ limit of the Credit Facilities was \$1,195,270, consisting of a term bank debt of \$457,015 and a revolving credit facility of \$738,255.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

5. LONG-TERM DEBT (continued):

The Credit Facilities are secured by substantially all of Chemtrade's assets. At March 31, 2021, the weighted average effective interest rate of the facilities was 4.2% (December 31, 2020 - 4.3%). Interest rates on the Credit Facilities are based on US LIBOR and Canadian Bankers' Acceptance rates, adjusted by Chemtrade's credit spread.

Chemtrade is subject to certain covenants pursuant to its Credit Facilities, which include a Net Debt to EBITDA ratio and an Interest Coverage ratio (as such terms are defined in the credit agreement). Chemtrade monitors these ratios and reports them to its lenders on a quarterly basis. As at March 31, 2021, Chemtrade was in compliance with all covenants.

6. CONVERTIBLE UNSECURED SUBORDINATED DEBENTURES:

Changes in convertible unsecured subordinated debentures are as follows:

	Convertible				
	Fund 2016 5.00% Debentures	Fund 2017 4.75% Debentures	Fund 2019 6.50% Debentures	Fund 2020 8.50% Debentures	Total
Maturity	August 31, 2023	May 31, 2024	October 31, 2026	September 30, 2025	
Interest rate	5.00 %	4.75 %	6.50 %	8.50 %	
Principal outstanding at January 1, 2021	143,750	201,115	100,000	86,250	531,115
Principal outstanding at March 31, 2021	143,750	201,115	100,000	86,250	531,115
Balance at January 1, 2021 Change in fair value recognized in profit or	126,500	156,870	78,000	84,525	445,895
loss	2,905	3,148	(2,544)	(1,253)	2,256
Change in fair value due to own credit risk (2)	10,032	24,204	18,044	9,921	62,201
Balance at March 31, 2021	139,437	184,222	93,500	93,193	510,352

⁽¹⁾ The Fund 2016 5.00% Debentures, the Fund 2017 4.75% Debentures, the Fund 2019 6.50% Debentures, the Fund 2020 8.50% Debentures and the Fund 2014 5.25% Debentures, which were redeemed during 2020 are collectively referred to as the "Fund Debentures". The Fund Debentures and the Chemtrade Electrochem Inc. ("CEI") Series VI Debentures, which were redeemed during the first quarter of 2020 are collectively referred to as the "Debentures". Chemtrade has designated the Debentures as financial liabilities at fair value through profit or loss.

(2) The change in fair value of the Debentures due to Chemtrade's own credit risk has been presented in other comprehensive income, net of taxes, rather than net earnings.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

6. CONVERTIBLE UNSECURED SUBORDINATED DEBENTURES (continued):

Convertible unsecured subordinated debentures (1) **Fund 2016 Fund 2017 Fund 2019 CEI Series Fund 2014** 5.25% 5.00% 4.75% 6.50% **Debentures Debentures Debentures Debentures Debentures Total** June 30, Maturity August 31, May 31, October 31, December 2021 2023 2024 2026 31, 2021 5.25 % 4.75 % 5.00 % 6.50 % 6.50 % Interest rate Principal outstanding at January 1, 74,584 2020 126,500 143,750 201,115 100,000 645,949 Principal outstanding at March 31, 2020 126,500 143,750 201,115 100,000 571,365 Balance at January 1, 2020 127,525 132,250 178,992 95,578 74,584 608,929 Redemption (2) (74,584)(74,584)Change in fair value recognized in profit 7,135 14,416 26,025 47,431 (145)or loss Change in fair value due to own credit (48,104)(46,603)risk ((23,649)(76,762)(195,118)Balance at March 31, 2020 103,731 91,281 116,646 75,000 386,658

For the three months ended March 31, 2021, interest expense of \$7,562 (2020 - \$7,490) relating to the Debentures was recognized in net finance costs.

⁽¹⁾ Chemtrade has designated the Debentures as financial liabilities at fair value through profit or loss.

⁽²⁾ During the first quarter of 2020, Chemtrade redeemed all of the outstanding CEI Series VI Debentures at a total aggregate redemption price of \$74,624, being equal to 100% of the principal amount of debentures outstanding, plus accrued and unpaid interest to, but excluding, the redemption date. Chemtrade used its Credit Facilities to fund the redemption.

⁽³⁾ The change in fair value of the Debentures due to Chemtrade's own credit risk has been presented in other comprehensive income, net of taxes, rather than net earnings.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

7. UNITS AND OTHER COMPONENTS OF EQUITY:

(a) Units:

Chemtrade has authorized an unlimited number of units. Chemtrade's units have no par value. The following table presents the number of units outstanding:

	2021		2020)
	Number of Units	Amount	Number of Units	Amount
Balance – January 1	93,169,158	\$ 1,465,029	92,601,062 \$	1,462,116
Issuance of units for cash	9,800,000	70,070	_	_
Issuance costs, net of tax recovery of \$1,188	_	(2,484)	_	_
Issuance of units under the DRIP	267,491	1,887	_	_
Balance – March 31	103,236,649	1,534,502	92,601,062 \$	1,462,116

On March 10, 2021, Chemtrade completed an equity offering of 9,800,000 units at a price of \$7.15 per unit, resulting in total gross proceeds of \$70,070. Chemtrade incurred issuance costs of \$2,484, net of tax recovery of \$1,188, which included underwriters' fees and other expenses relating to the offering. Proceeds from the offering were used to repay outstanding indebtedness under the Credit Facilities and for general trust purposes.

(b) Distributions:

On March 11, 2020, Chemtrade announced a reduction of its monthly distributions to \$0.05 per unit.

On July 13, 2020, Chemtrade announced the commencement of a DRIP. Under the terms of the DRIP, eligible Unitholders may elect to reinvest all or a portion of their regular monthly distributions in additional units of Chemtrade, without paying any commissions, service charges or brokerage fees under the DRIP. Units purchased for participants under the DRIP may be newly issued by Chemtrade from treasury or may be existing units purchased on the open market through the facilities of a stock exchange. Under the DRIP, the Board determines which of these two sources will be used and currently the units are issued from treasury. Currently, the participants receive bonus distributions of Units equal to 3% of the amount of the cash distribution reinvested, as determined by the Board.

Distributions paid for the three months ended March 31, 2021 were \$14,044 (2020 - \$27,780) or \$0.15 per unit (2020 - \$0.30 per unit). Of the distributions paid for the three months ended March 31, 2021, \$12,157 (2020 - \$27,780) were in cash and \$1,887 (2020 - nil) were reinvested in additional units pursuant to the DRIP. All of Chemtrade's distributions are discretionary and subject to Board approval.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

7 LINITE AND OTHER COMPONENTS OF FOURTY (continued):

7. UNITS AND OTHER COMPONENTS OF EQUITY (continued):

Distributions declared, including the bonus distributions for the three months ended March 31, 2021 were \$14,554 (2020 - \$23,150) or \$0.15 per unit (2020 - \$0.25 per unit).

As at March 31, 2021, Chemtrade had \$5,187 distributions payable. On April 27, 2021, distributions of \$4,339 were paid in cash and \$848 were reinvested in additional units pursuant to the DRIP. On April 21, 2021, Chemtrade declared a cash distribution of \$0.05 per unit for the month of April 2021 payable on May 26, 2021 to Unitholders of record at the close of business on April 30, 2021.

(e) Net loss per unit:

Net loss per unit has been calculated on the basis of the weighted average number of units outstanding. The following tables provide a breakdown of the numerator and denominator used in the calculation of net loss per unit, and diluted net loss per unit:

	I	hree months end	ed March 31,
		2021	2020
Numerator			
Net loss	\$	(20,448) \$	(97,875)
Net interest and fair value adjustment on the Debentures (1)		_	_
Net fair value adjustment on deferred unit plan (2)		_	_
Diluted net loss	\$	(20,448) \$	(97,875)

⁽¹⁾ For the three months ended March 31, 2021 and 2020, the potential conversion of the Debentures have not been included as the effect on net loss per unit would be anti-dilutive.

⁽²⁾ For the three months ended March 31, 2021, the potential conversion of the deferred units have not been included as the effect on net loss per unit would be anti-dilutive. For the three months ended March 31, 2020, the deferred units would have been settled on the secondary market and therefore, had no potential dilutive effect on net loss. See Note 9.

	Three months end	Three months ended March 31,		
	2021 2020			
Denominator				
Weighted average number of units	95,673,137	92,601,062		
Weighted average Debentures dilutive units (1)	_	_		
Weighted average deferred unit plan dilutive units (2)	_	_		
Weighted average number of diluted units	95,673,137	92,601,062		

⁽¹⁾ For the three months ended March 31, 2021 and 2020, the potential conversion of the Debentures have not been included as the effect on net loss per unit would be anti-dilutive.

⁽²⁾ For the three months ended March 31, 2021, the potential conversion of the deferred units have not been included as the effect on net loss per unit would be anti-dilutive. For the three months ended March 31, 2020, the deferred units would have been settled on the secondary market and therefore, had no potential dilutive effect on net loss. See Note 9.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

8. GOODWILL IMPAIRMENT:

During the first quarter of 2020, as a result of changes in macro-economic conditions which resulted in a significant increase in discount rates, combined with consideration of historic and forecast performance of each cash-generating unit ("CGU") and CGU group, Chemtrade performed a test for goodwill impairment for the water solutions CGU group in WSSC. Although the water solutions CGU group's operating performance had been improving, as a result of applying the higher discount rate, this CGU group's carrying value exceeded its recoverable amount by \$56,000 and therefore an impairment loss of \$56,000 was fully allocated to goodwill and recognized in cost of sales and services. Following the impairment recognized in the water solutions CGU group, its recoverable amount equalled its carrying value.

The impairment test in the first quarter of 2020 was performed using a pre-tax discount rate of 12.8% and a terminal growth rate of 2.5%. Assumptions used in the operating cash flows and maintenance and other expenditures consider financial budgets, past experience, future growth trends such as GDP growth and inflation, associated economic risk assumptions, assumptions regarding the speed of COVID-19 economic recovery and estimates of achieving key operating initiatives, covering a five year period.

During the first quarter of 2021, there were no indicators of impairment identified; therefore, Chemtrade did not perform a test for goodwill impairment.

9. SHARE-BASED PAYMENTS:

Chemtrade operates a Long Term Incentive Plan ("LTIP"), which grants cash awards based on certain criteria. The 2019 - 2021, 2020 - 2022 and 2021 - 2023 LTIP awards have a performance based component and a restricted share unit component. The performance based component of the 2019 - 2021 LTIP awards is based on total Unitholder return over a performance period, EBITDA growth and total return to Chemtrade's Unitholders relative to the total return of companies comprising the S&P/TSX Dividend Composite Index. The performance based component of the 2020 - 2022 and 2021 - 2023 LTIP awards is based on return on investment capital improvement and total return to Chemtrade's Unitholders relative to the total return of companies comprising the S&P/TSX Dividend Composite Index. Total Unitholder return consists of changes in unit price and distributions paid to Unitholders. The restricted share unit component of the LTIP awards is a phantom plan which is payable in cash at the end of the performance period.

As at March 31, 2021, a liability of \$18,554 (December 31, 2020 - \$19,384) has been recorded, of which \$5,836 (December 31, 2020 - \$5,126) is included in trade and other payables and \$12,718 (December 31, 2020 - \$14,258) is included in other long-term liabilities. For the three months ended March 31, 2021, Chemtrade recorded an expense of \$5,649 (2020 - recovery of \$5,634) in selling and administrative expenses related to the fair value adjustments on the LTIP.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

9. SHARE-BASED PAYMENTS (continued):

Chemtrade has in place a deferred unit plan ("DUP") for non-employee trustees and directors ("Participants"), pursuant to which the Participants can elect to take all or a portion of their compensation in the form of deferred units of Chemtrade, with the remainder as a cash payment. On May 14, 2020, the DUP was amended. Prior to the amendment, deferred units could be redeemed for cash or units of the Fund purchased on the secondary market. Following the amendment, deferred units are settled in units of the Fund issued from treasury or in cash at the Participant's request. Currently, the Participants are required to take a minimum of 50% of their compensation in the form of deferred units of Chemtrade. As at March 31, 2021, 519,967 deferred units at a value of \$3,593 were outstanding (December 31, 2020 - 556,948 deferred units at a value of \$3,286).

Inputs for measurement of fair values

The fair value of the share-based component of LTIP is measured based on the Monte Carlo simulation method. Base price is the average unit price for the first 20 business days at the beginning of each LTIP performance period. Expected volatility is estimated by considering historic average unit price volatility. The risk-free interest rate is based on Canadian government bonds and Canadian government treasury bills.

The inputs used in the measurement of the fair value of the share-based component of LTIP are as follows:

	March 31, 2021	December 31, 2020
Chemtrade units:		
Average base price	\$10.15	\$14.01
Period-end unit price	\$6.86	\$5.83
Average expected volatility	39.25%	57.18%
Average risk free interest rate	0.14%	0.10%
Average expected remaining term	1.75 years	1.50 years

10. REVENUE:

The revenues for Chemtrade are as follows:

	<u>Thi</u>	Three months ended March 31,			
		2021 20			
Sales of products	\$	279,044 \$	324,950		
Processing services		33,396	41,951		
	\$	312,440 \$	366,901		

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

11. SELLING AND ADMINISTRATIVE EXPENSES:

The components of selling and administrative expenses are as follows:

	Three months ended March 31,			
		2021	2020	
Wages, salaries and benefits, including bonuses and other	\$	29,772 \$	18,311	
Realized foreign exchange loss		780	1,665	
Unrealized foreign exchange loss		430	9,608	
Depreciation (note 13)		1,053	904	
Reserve for legal proceedings		1,091	_	
Government grants		(4,651)		
Selling and administrative expenses	\$	28,475 \$	30,488	

Reserve for legal proceedings

General Chemical (which was acquired by Chemtrade) was a subject of an investigation by the U.S. Department of Justice concerning alleged anti-competitive conduct in the water treatment chemicals industry, for which General Chemical obtained the benefit of conditional amnesty from criminal charges. General Chemical and Chemtrade were also defendants in class action lawsuits and a few civil proceedings relating to the same conduct. Corporate costs for the year ended December 31, 2019 included an expense of \$40,000 which increased the reserve for the costs of litigating and resolving all of the civil actions commenced against General Chemical and Chemtrade and various other defendants for anti-competitive actions in the water business. The main class action civil lawsuit was settled for US\$56,000 and was paid out during 2019. By the third quarter of 2019, additional settlements were negotiated and paid. The remaining exemployee initiated derivative actions were settled in March 2021, at close to the amount previously reserved for this matter. The terms of the settlement are subject to finalization and approval by the relevant governmental entities and courts. The reserve for legal proceedings is included as part of provisions and presented as current liabilities in the Condensed Consolidated Interim Statements of Financial Position.

Government grants

The Canada Emergency Wage Subsidy ("CEWS") was announced on March 27, 2020. Under this program, qualifying businesses can receive up to 75% of their employees' wages, with employers being encouraged to provide the remaining 25%. Although the legislation was finalized on April 11, 2020, interpretations and guidance continue to emerge. Eligible employers can start recognizing the subsidy as a receivable from the date the legislation was finalized provided there is reasonable assurance that they have met the relevant conditions and will continue to comply with the conditions for receipt of the subsidy. Chemtrade believes that it will continue to comply with the conditions for receipt of the subsidy.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

11. SELLING AND ADMINISTRATIVE EXPENSES (continued):

The Canada Emergency Rent Subsidy ("CERS") provides rent and mortgage support to businesses affected by COVID-19. Under this program, businesses that experience a revenue drop will be eligible to claim a subsidy on eligible expenses. CERS is administered by the Canada Revenue Agency ("CRA") on a period-by-period basis. Each CERS claim period is four weeks, and businesses can generally submit a claim the day after the period has ended. The subsidy is available on a sliding scale (with a maximum amount of 65%) for businesses that can demonstrate a revenue loss from September 27, 2020 to June 5, 2021. Chemtrade has performed its assessment and believes it is eligible for this subsidy.

During the three months ended March 31, 2021, Chemtrade received CEWS of \$5,296. Of the amounts received during the three months ended March 31, 2021, \$2,395 was related to a receivable recorded as at December 31, 2020. As at March 31, 2021, Chemtrade recorded CEWS and CERS receivables of \$1,425 and \$325 respectively in trade and other receivables in the condensed consolidated interim statement of financial position.

12. NET FINANCE COSTS:

The components of net finance costs are as follows:

	Thre	Three months ended March 31,			
		2021	2020		
lada a sada a sana a sana la sana da sana da bad	•	0.005 *	0.407		
Interest expense on long-term debt	\$	9,265 \$	9,127		
Interest expense on convertible debentures (note 6)		7,562	7,490		
Change in the fair value of convertible debentures (note 6)		2,256	47,431		
Interest expense on lease liabilities		1,719	2,163		
Accretion expense on financing transaction costs (note 5)		282	185		
Accretion of provisions		400	762		
Pension interest		239	386		
Interest income		(225)	(92)		
Net finance costs	\$	21,498 \$	67,452		

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

13. DEPRECIATION AND AMORTIZATION:

The components of depreciation expense of PPE and ROU assets and amortization expense of intangible assets are as follows:

	Thre	Three months ended March 31,			
		2021	2020		
Cost of sales and services:					
Depreciation expense on PPE	\$	33,805 \$	34,442		
Depreciation expense on ROU assets		11,814	12,350		
Amortization expense		15,721	16,221		
Selling and administrative expenses (note 11):					
Depreciation expense on PPE		603	430		
Depreciation expense on ROU assets		450	474		
Total depreciation and amortization expense	\$	62,393 \$	63,917		

14. INCOME TAXES:

Chemtrade is a mutual fund trust and a specified investment flow-through trust ("SIFT") for income tax purposes. Chemtrade is subject to current income taxes at the top marginal tax rate applicable to individuals of approximately 53.5% on all taxable income not distributed to Unitholders.

Chemtrade is also subject to current income taxes on all taxable income, other than dividends, earned from Canadian corporate and flow-through subsidiaries (other than Canadian subsidiaries that earn certain investment income) at a tax rate similar to the corporate tax rate. Chemtrade will not be subject to tax on income received from non-Canadian subsidiaries, provided that the income is distributed to Unitholders during the year. Based on the current organization of Chemtrade and its subsidiaries, Chemtrade expects that its income distributed to Unitholders will not be subject to SIFT tax.

Income tax expense is recognized based on management's best estimate of the weighted average annual income tax rate expected for the full financial year applied to the pre-tax income of the interim period. Chemtrade calculates the consolidated estimated effective annual tax rate by determining the amount of current and deferred income taxes as a percentage of income before tax. Chemtrade's consolidated estimated effective tax rate for the three months ended March 31, 2021 was 29.6% (2020 - 17.7%), compared to a statutory rate of 26.0% (2020 - 26.4%).

The effective tax rate for the first quarter of 2021 differs from the statutory tax rate primarily due to the deduction of taxable income distributed to Unitholders, differences in domestic corporate and trust tax rates, and certain permanent differences.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

14. INCOME TAXES (continued):

Chemtrade is subject to tax audits from various tax authorities on an ongoing basis. As a result, from time to time, tax authorities may disagree with the positions and conclusions taken by Chemtrade in its tax filings or legislation could be amended or interpretations of current legislation could change, any of which events could lead to reassessments.

15. FINANCIAL INSTRUMENTS:

(a) Derivatives and hedging:

	March 31, 2021						December 31, 2020			
	Notional	Fair Value			Notional	Fair Value		Value		
	Amount	As	set	L	iability	Amount	Α	sset	Liability	
Derivatives designated in a formal hedging relationship										
Interest rate swaps	US\$ 575,000	\$	_	\$	18,033	US\$ 575,000	\$	_	\$ 22,164	
Total		\$	_	\$	18,033		\$	_	\$ 22,164	

On January 24, 2019, Chemtrade entered into swap arrangements which fixed the LIBOR components of its interest rates on US\$175,000 of its outstanding term bank debt until December 2023. Chemtrade entered into additional swap arrangements which were effective August 24, 2019 and which fixed the LIBOR components of its interest rates on US\$150,000 of its outstanding term bank debt until December 2023. On April 24, 2020, Chemtrade entered into a swap arrangement which fixed the LIBOR components of its interest rates on up to US\$250,000 of its outstanding revolving credit under its long term debt until it expired on April 24, 2021. These swaps are formally designated as cash flow hedges at the date of inception and any changes in the fair value of the effective portion of the swaps are recognized in other comprehensive income.

During the first quarter of 2021, Chemtrade blended and extended its existing US\$175,000 and US\$150,000 interest rate swaps on its outstanding term bank debt. Effective March 24, 2021, the terms of these swaps were extended until October 2024 to align with the maturity date of the term bank debt. Chemtrade recognizes the blend and extend as a termination of the original swaps and execution of new swaps. As a result, hedge accounting on the original swaps were discontinued prospectively. To continue the benefits of hedge accounting, Chemtrade designated the new blend and extend swaps in new hedge relationships. Since the interest payments that are being hedged are still expected to occur, the fair values of the old swaps as of the termination date will remain in accumulated other comprehensive income and reclassified into net earnings over the term of original swaps.

Chemtrade hedges its investment in foreign operations that use the U.S. dollar as their functional currency by Chemtrade's U.S. dollar-denominated long-term debt. Any foreign currency gains and losses arising from the U.S. dollar-denominated debt will be offset by the foreign currency gain or loss arising from the investment in the foreign operations. The gains

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

15. FINANCIAL INSTRUMENTS (continued):

and losses on the foreign currency translation of the designated amount of U.S. dollardenominated debt and investment in foreign operations are recognized in other comprehensive income.

For the three months ended March 31, 2021, a foreign exchange gain of \$8,586 (2020 - loss of \$54,392) on the revaluation of the U.S. dollar-denominated debt related to this hedging strategy was recognized in other comprehensive income, net of tax.

Chemtrade enters into foreign exchange contracts to manage some of its exposure to foreign currencies. Chemtrade buys and sells specific amounts of currencies at pre-determined dates and exchange rates, which are matched with the anticipated operational cash flows. As at March 31, 2021, there were no foreign exchange contracts in place.

(b) Fair values of financial instruments:

Fair value is the value that would be agreed upon in an arm's length transaction between willing and knowledgeable counter-parties. The carrying amounts of cash and cash equivalents, trade and other receivables, trade and other payables and distributions payable approximate their fair values because of the short-term maturity of these financial instruments. The carrying amount of long-term debt, excluding transaction costs, approximates fair value as the debt accrues interest at variable interest rates.

For fair value estimates relating to the Debentures and derivatives, Chemtrade classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - Unadjusted quoted prices at the measurement date for identical assets or liabilities in active markets.

Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 - Significant unobservable inputs which are supported by little or no market activity.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

15. FINANCIAL INSTRUMENTS (continued):

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The Debentures are classified within Level 1 because they are actively traded on the TSX and the fair value is based on the quoted prices on the TSX. Any changes in the fair value of the Debentures are recognized in net earnings except for changes due to the Fund's own credit risk which are recorded in other comprehensive income.

All of Chemtrade's derivative financial instruments are classified within Level 2 because they are based on rates quoted by banks and other public data sources. These derivatives are recorded in prepaid expenses and other assets, trade and other payables, and other long-term liabilities on the statements of financial position.

The fair value of the foreign exchange contracts is the difference between the forward exchange rate and the contract rate. Any changes in the fair value of these contracts are recognized in net earnings.

The fair value of the interest rate swap arrangements is the difference between the forward interest rates and the contract rates discounted. The liability is recorded in other long-term liabilities in the statement of financial position. Any changes in the effective portion of fair value of these arrangements are recognized in other comprehensive income.

(c) Risks associated with financial instruments

(i) Credit risk

Credit risk arises from the non-performance by counter-parties of their contractual financial obligations. Chemtrade manages credit risk for trade and other receivables through established credit monitoring activities. Chemtrade does not have a significant concentration of credit risk with any single counter-party. The primary counter-parties related to the foreign exchange forward contracts and interest rate swaps carry investment grade ratings. Chemtrade believes its credit risk of counterparty non-performance continues to be relatively low, notwithstanding the impact of the COVID-19 pandemic. Chemtrade is in regular contact with its customers, suppliers and logistics providers, and to date has not experienced significant counter-party non-performance. However, if a key supplier or customer experiences financial difficulties or fails to comply with their contractual obligations, which may occur as the pandemic continues, this could result in a significant financial loss to Chemtrade. Chemtrade's maximum exposure to credit risk at the reporting date is the carrying value of its receivables and derivative assets.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

15. FINANCIAL INSTRUMENTS (continued):

(ii) Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. Chemtrade manages liquidity risk by maintaining adequate cash and cash equivalent balances, and by appropriately utilizing its lines of credit. Chemtrade believes that cash flows from operating activities, together with cash on hand, cash from receivables and borrowings available under the revolving credit facility are sufficient to fund its currently anticipated financial obligations, and will remain available in the current environment, notwithstanding the impact of the COVID-19 pandemic.

(iii) Currency risk

Chemtrade is exposed to fluctuations in the exchange rate of the US dollar relative to the Canadian dollar as a portion of Chemtrade's earnings are in US dollars, with earnings positively affected when the US dollar strengthens relative to the Canadian dollar. Chemtrade cannot predict changes in currency exchange rates, the impact of exchange rate changes on Chemtrade's operating results, nor the degree to which Chemtrade will be able to manage the impact of currency exchange rate changes. Such changes, including negative impacts on currency exchange rates related to the COVID-19 pandemic, could have an impact on Chemtrade's business, results of operations and financial condition.

(iv) Interest rate risk

Chemtrade's Credit Facilities consist of long-term debt and operating lines of credit which bear variable rates of interest. As at March 31, 2021, on an unhedged basis, a change in interest rates of 1% per annum would have an impact of approximately \$7,500 on Chemtrade's net earnings per annum. As at March 31, 2021, Chemtrade had fixed interest rates on 96.9% of its senior debt until April 2021 and 54.8% thereafter until October 2024.

Managing interest rate benchmark reform and associated risks

A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some IBORs with alternative nearly risk-free rates ("RFR"). Chemtrade has exposures to IBORs on its financial instruments that will be replaced or reformed as part of these market-wide initiatives. There is uncertainty over the timing and the methods of transition in some jurisdictions that Chemtrade operates in.

The IBOR reform impacts Chemtrade's operational and risk management processes and hedge accounting. The main risks to which Chemtrade is exposed as a result of the IBOR

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

15. FINANCIAL INSTRUMENTS (continued):

reform are operational. This includes renegotiating borrowing contracts through bilateral negotiation with counterparties, implementing new fallback clauses with its derivative counterparties, updating contractual terms and revising operational controls related to the reform. Financial risk is predominantly limited to interest rate risk. Hedging relationships may experience ineffectiveness due to uncertainty about when and how replacement may occur with respect to the relevant hedged item and hedging instrument or the difference in the timing of a replacement.

Chemtrade monitors the progress of transition from IBORs to new benchmark rates by reviewing the total amounts of contracts that have yet to transition to an alternative benchmark rate and the amounts of such contracts that include an appropriate fallback clause. Chemtrade considers that a contract is not yet transitioned to an alternative benchmark rate when interest under the contract is indexed to a benchmark rate that is still subject to IBOR reform, even if it includes a fallback clause that deals with the cessation of the existing IBOR (referred to as an 'unreformed contract').

Derivatives

Chemtrade holds interest rate swaps for risk management purposes which are designated in cash flow hedging relationships. The interest rate swaps have floating legs that are indexed to 1-month LIBOR. Chemtrade's derivative instruments are governed by contracts based on the International Swaps and Derivatives Association (ISDA)'s master agreements.

ISDA is currently reviewing its standardized contracts in the IBOR reform and plans to amend certain floating-rate options in the 2006 ISDA definitions to include fallback clauses that would apply on the permanent discontinuation of certain key IBORs. ISDA is expected to publish an IBOR fallback supplement to amend the 2006 ISDA definitions and an IBOR fallback protocol to facilitate multilateral amendments to include the amended floating-rate options in derivative transactions that were entered into before the date of the supplement. Chemtrade will adhere to the protocol if and when it is finalized and monitor whether its counterparties will adhere. If this plan changes or there are counterparties who will not adhere to the protocol, Chemtrade will negotiate with them bilaterally about including new fallback clauses.

Hedge accounting

Chemtrade's hedged items and hedging instruments continue to be indexed to 1-month LIBOR. These benchmark rates are quoted each day and the IBOR cash flows are exchanged with counterparties as usual.

Chemtrade's exposure to 1-month LIBOR designated in hedging relationships is US\$575,000 nominal amount at March 31, 2021, representing both the nominal amount

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

15. FINANCIAL INSTRUMENTS (continued):

of the hedging interest rate swap and the principal amount of the hedged USD denominated secured bank loan liability maturing in October 2024. Of the US\$575,000 nominal amount outstanding at March 31, 2021, US\$250,000 relating to the hedge on the revolving credit facility expired on April 24, 2021.

The IBOR reform had no impact on the interim condensed consolidated financial statements of Chemtrade. Chemtrade intends to use the RFR for its risk management and hedge accounting in future periods if it becomes applicable. Chemtrade will actively monitor the IBOR reform and consider circumstances as it becomes party to new or revised interest rate swaps.

16. REPORTABLE SEGMENTS:

Chemtrade operates in four reportable segments: SPPC, WSSC, EC, and Corp. The reportable segments of Chemtrade are strategic business groups that offer products and services to target markets, as described below. The accounting policies applied by the segments are the same as those applied by Chemtrade.

SPPC markets, removes and/or produces merchant, regenerated and ultra pure sulphuric acid, sodium hydrosulphite, elemental sulphur, liquid sulphur dioxide, hydrogen sulphide, sodium bisulphite, and sulphides, and provides other processing services. These products are marketed primarily to North American customers.

WSSC manufactures and markets a variety of inorganic coagulants used in water treatment, including aluminum sulphate, aluminum chlorohydrate, polyaluminum chloride, and ferric sulphate; and a number of specialty chemicals, including sodium nitrite, potassium chloride (KCI), phosphorus pentasulphide and vaccine adjuvants. These products are marketed primarily to North American customers.

EC manufactures and markets sodium chlorate and chlor-alkali products including caustic soda, chlorine and hydro-chloric acid (HCI), largely for the pulp and paper, oil and gas and water treatment industries. These products are marketed primarily to North American and South American customers.

Corp is a non-operating segment that provides centralized services, such as treasury, finance, information technology, human resources, legal and risk management, and environmental, health and safety support.

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

16. REPORTABLE SEGMENTS (continued):

Three months ended March 31, 2021

	SPPC	WSSC	EC	Corp	Total
Revenue	\$ 91,967 \$	98,786	\$ 121,687 \$	— \$	312,440
Inter-segment revenues	4,474	_	921	_	5,395
Operating income (loss)	5,489	11,189	(2,271)	(21,953)	(7,546)
Net finance costs					(21,498)
Income tax recovery					8,596
Net loss					(20,448)
Depreciation and amortization	22,470	10,532	29,391	_	62,393
Net loss on disposal and write-down of PPE	12	82	57	_	151
Capital expenditures	1,438	2,137	5,073	121	8,769

Three months ended March 31, 2020

	SPPC	WSSC	EC	Corp	Total
Revenue	\$ 113,022	\$ 113,338	\$ 140,541	\$ — \$	366,901
Inter-segment revenues	3,536	_	1,204	_	4,740
Operating income (loss)	11,513	(45,294)	4,236	(21,999)	(51,544)
Net finance costs					(67,452)
Income tax recovery					21,121
Net loss					(97,875)
Depreciation and amortization	23,168	12,076	28,673	_	63,917
Net (gain) loss on disposal and write-down of PPE	(49)	(457)	24	_	(482)
Change in environmental liability	_	3,381	_		3,381
Impairment of goodwill	_	56,000	_	_	56,000
Capital expenditures	2,151	1,323	8,016	299	11,789

March 31, 2021

	SPPC	WSSC	EC	Corp	Other	Total
Total assets	\$ 839,435 \$	591,086 \$	882,734 \$	666 \$	139,753 \$	2,453,674
Total liabilities	198,616	143,931	186,355	51,111	1,267,638	1,847,651
Intangible assets	352,500	165,513	209,733	_	_	727,746

Notes to Condensed Consolidated Interim Financial Statements (In thousands of Canadian dollars, except per unit amounts) (Unaudited)

Three months ended March 31, 2021 and 2020

16. REPORTABLE SEGMENTS (continued):

December 31, 2020

	SPPC	WSSC	EC	Corp	Other	Total
Total assets	\$ 862,605 \$	607,728 \$	906,249 \$	3,762 \$	119,982 \$	2,500,326
Total liabilities	220,755	172,240	215,235	50,043	1,236,238	1,894,511
Intangible assets	361,469	169,939	216,662	_	_	748,070

Geographic segments:

Chemtrade operates primarily in Canada, the United States and South America. Revenue is attributed to customers based on location of sale.

Revenue

	<u>Th</u>	Three months ended March 31,				
		2021	2020			
Canada	\$	105,103 \$	117,309			
United States		190,704	232,201			
South America		16,633	17,391			
	\$	312,440 \$	366,901			

PPE, ROU assets and intangible assets

	March 31, 2021	December 31, 2020
Canada	\$ 959,388	\$ 997,912
United States	803,060	834,705
South America	113,040	117,683
	\$ 1,875,488	\$ 1,950,300

17. RECLASSIFICATION OF PRIOR PERIOD PRESENTATION:

Certain amounts reported in prior periods in the financial statements have been reclassified to conform to the current period's presentation.

18. SUBSEQUENT EVENTS:

Amendment of Credit Facilities terms

In May 2021, Chemtrade modified certain terms of its Credit Facilities including negotiating an amended covenant package on its Credit Facilities to provide Chemtrade with additional covenant room until 2023.

Information for Unitholders

Trustees

Lorie Waisberg (Chair)

Toronto, Ontario

Scott Rook

Toronto, Ontario

Lucio Di Clemente

Toronto, Ontario

Daniella Dimitrov

Toronto, Ontario

Emily Moore

Toronto, Ontario

Douglas Muzyka

Philadelphia, Pennsylvania

Katherine Rethy

Huntsville, Ontario

Management

Scott Rook

President & CEO

Leon Aarts

Group Vice-President, Commercial

Rohit Bhardwaj

Chief Financial Officer

Tejinder Kaushik

Vice-President, Information Technology

Timothy Montgomery

Group Vice-President,

Manufacturing & Engineering

Susan Paré

Corporate Secretary

General Counsel

Emily Powers

Group Vice-President,

Human Resources and Responsible Care

Head Office

155 Gordon Baker Road, Suite 300

Toronto, Ontario, Canada

M2H 3N5

Stock Exchange Listing

Toronto Stock Exchange

Stock symbol: CHE.UN

Transfer Agent and Registrar

Computershare Trust Company of Canada

100 University Avenue, 8th Floor

Toronto, Ontario M5J 2Y1

Telephone

Toll free 1-800-564-6253

Email

service@computershare.com

Website

computershare.com

Investor information

Unitholders or other interested parties seeking financial information about the Fund are invited to call:

Rohit Bhardwaj

Ryan Paull

Chief Financial Officer

Business Development Manager

(416) 496-5856 (973) 515-1831

chemtradelogistics.com



Chemtrade Logistics Income Fund 155 Gordon Baker Road Suite 300 Toronto, Ontario M2H 3N5

